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Parkinson’s disease is the second most common neurodegenerative disorder; it is 
estimated that one million people in the United States have Parkinson's disease.  Some 
50,000 new cases are diagnosed each year and the disease is expected to impose an 
increasing social and economic burden on societies as populations age. The current gold 
standard of care for Parkinson’s disease is treatment with dopamine precursors which 
only temporarily alleviate the motor symptoms, but do nothing to prevent further 
neuronal death.  In 2003, the gene DJ-1 was associated with early-onset autosomal 
recessive Parkinson’s disease.  Because loss-of-function mutations in DJ-1 cause 
Parkinson’s disease, we theorized that therapies aimed at up-regulating DJ-1 levels could 
stop disease progression.  After screening a number of small molecules, we found that the 
drug phenylbutyrate increased DJ-1 expression three-fold in a dopamine neuron cell line 
and up-regulated a number of neuroprotective mechanisms such as oxidative stress 
response, chaperone-mediated proteasomal degradation and lysosome and exosome 
protein elimination pathways.  In our transgenic mouse model of diffuse Lewy body 
disease, phenylbutyrate up-regulates DJ-1, enhances clearance of toxic α-synuclein 
aggregates and prevents age-related deterioration of motor and cognitive function.  
Additionally, in a human Phase I clinical safety trial, phenylbutyrate treatment showed no 
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adverse effects and enhanced α-synuclein mobilization into blood plasma. Additionally, 
clinical trials have found regular exercise can improve and retain motor function in 
Parkinson’s patients; however, it is still unknown whether exercise can prevent the 
biological hallmarks of disease.  In our transgenic mouse model of diffuse Lewy body 
disease, we have found that voluntary running wheel exercise is sufficient to up-regulate 
brain DJ-1, thereby increasing α-synuclein clearance to the plasma and reducing 
cognitive and motor decline.  My research findings conclude that therapies aimed at up-
regulating the neuroprotective gene DJ-1, such as phenylbutyrate treatment or exercise 
intervention, may slow the relentless progression of Parkinson’s disease by preventing 
further dopamine neuron degeneration.   
My research approach is to target and up-regulate the neuroprotection gene DJ-1 
and activate protection pathways in order to halt the progression of disease.  Studies done 
prior to my thesis research revealed that DJ-1 is able to activate oxidative stress response 
pathways when cells are exposed to reactive oxygen species toxins.  Separately, DJ-1 is 
able to up-regulate chaperone proteins when cells are exposed to protein aggregate 
toxins.  From these preliminary findings I formulated the following hypothesis:  Since 
DJ-1 neuroprotective, any therapy that could up-regulate DJ-1 without being harmful to 
cells could activate neuroprotection pathways in dopamine neurons in Parkinson’s 
patients thereby preventing future neuronal death and stopping the progression of disease. 
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History and clinical manifestations 
James Parkinson first described the hallmark features of Parkinson’s disease in 
“An Essay on the Shaking Palsy” (Parkinson, 1817); this established Parkinson’s disease 
as a recognized medical condition.  Parkinson’s disease is the second most common 
neurodegenerative disorder after Alzheimer’s disease.  It is estimated that between four 
and six million people worldwide and one million people in the United States have 
Parkinson's disease.  Some 50,000 new cases are diagnosed each year and the disease is 
expected to impose an increasing social and economic burden on societies as populations 
age (de Lau et al, 2006).  Most cases begin between the ages of 50 and 65, with the 
average age of onset at about 60 years.  Parkinson’s disease is a complex disease that is 
clinically characterized by the presence of diverse motor symptoms that include:  tremor 
at rest, rigidity, bradykinesia or slowness of movement, impaired or stooped posture, loss 
of balance, loss of automatic movements like smiling or gesturing while speaking, and 
changes in speech and writing.  Signs and symptoms vary from patient to patient and 
usually develop unilaterally—meaning symptoms begin on one side of the body and 
remain worse on that side, even after symptoms affect both sides. Parkinson’s disease is a 
progressive disorder and the symptoms will get worse over time.   
In 1960, the predominant neurochemical impairment in Parkinson’s disease was 
recognized to be a dopamine deficiency in brain regions involved in movement control 
(Ehringer et al, 1960).  Voluntary motor activity is controlled by the primary motor 
cortex which receives information about planning and motivation to start motor activity 
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from the basal ganglia.  The main components of the basal ganglia are the globus 
pallidus, the subthalamic nucleus, the striatum—which consists of the caudate and 
putamen—and the substantia nigra (Fig 1).  
 
Figure 1: Coronal cross section of the basal ganglia 
The basal ganglia is comprised of many regions of the brain that organize muscle-driven 
motor movements of the body.  The major divisions of the basal ganglia are the caudate 
nucleus, putamen, globus pallidus and substantia nigra.  Many of the symptoms of 
movement disorders such as Parkinson’s disease and Huntington’s disease result from 




Substantia nigra is Latin for “black substance” because this brain region appears 
darker than neighboring areas due to high levels of melanin in dopaminergic neurons, 
which localize to the substantia nigra.  In patients with Parkinson’s disease, the substantia 
nigra region lacks the natural dark pigment because the dopaminergic neurons have died 
(Fig. 2).  The basal ganglia controls a complex set of excitatory glutamatergic and 
inhibitory GABAergic pathways between the substantia nigra and the striatum via the 
nigrostriatal pathway (Purves et al, 2012).  In healthy individuals, dopaminergic neuron 
activity increases and dopamine is released in the nigrostriatal pathway when movement 
is initiated.  When one of these components is compromised, the motor systems cannot 




movement. In Parkinson’s patients, dopaminergic neurons have degenerated and the pool 
of dopamine is depleted in the nigrostriatal pathway resulting in the clinical motor 
symptoms. 
In 1962, early clinical researchers of Parkinson’s disease published the following 
finding:  “The low levels of dopamine cause the degeneration of nerve cells in part of the 
brain called the substantia nigra” (Birkmayer et al, 1962).  It was this discovery that lead 
to the first effective medical treatment of the disease.  However, it is now understood that 
the loss of dopamine is not the cause of neuronal death; instead, dopamine depletion is 
the effect of dopaminergic neuronal death caused by other factors.   It is hypothesized 
that the deregulated opening and closing of L-type calcium channels during autonomous 
pace-making results in sustained calcium entry to the cytoplasm of dopamine neurons.  
Elevated calcium level is thought to disrupt intercellular redox equilibrium resulting in 
elevated mitochondrial oxidative stress and susceptibility to environmental toxins and 
aggregated proteins (Guzman et al, 2010).  Still, these researchers were accurate in their 
hypothesis that loss of the neurotransmitter is sufficient to cause the symptoms of 
Parkinson’s disease and they were able to use this finding to develop effective treatment 
for these symptoms. 
Current treatment 
The current treatments for Parkinson’s disease include drugs that attempt to 
temporarily improve symptoms.  In the late 1960s the drug Levodopa, L-DOPA, was first 
administered to treat the symptoms and has since become the “gold standard” in 
medication for Parkinson’s disease (Cotzias, 1968).  L-DOPA is the precursor to the 




Figure 2: Dopamine neurons localize to the substantia nigra 
Substantia nigra is dark in pigment due to the melanin-containing dopamine neurons that 
co-localize to this region.  The substantia nigra region in the brain of a Parkinson’s 
disease patient has lost the pigmentation because the dopamine neurons have 

















Doses vary, but L-DOPA is usually administered multiple times daily.  L-DOPA 
can cross the blood-brain barrier—whereas dopamine itself cannot—where it is quickly 
converted to dopamine by the enzyme DOPA decarboxylase. The dopamine metabolized 
from L-DOPA temporarily replenishes the depleted dopamine pool in the motor regions 
of the brain and can temporarily alleviate motor symptoms (Fig. 3).  
 
Figure 3: L-DOPA is the most common current treatment for Parkinson’s disease 
L-DOPA is the “gold standard” treatment for Parkinson’s disease.  It is converted to 
dopamine in the brain and temporarily alleviates motor symptoms; but, it cannot stop the 
relentless degeneration of dopamine neurons or stop disease progression. Adapted from 
Hornykiewicz O., 2002. 
 
 
Environmental causes of Parkinson’s disease 
Epidemiological studies consistently link exposure to pesticides to a higher 
incidence of Parkinson’s disease. In particular, pesticides that cause an increase in 
reactive oxygen species (ROS), such as rotenone and paraquat, have been shown to cause 
Parkinson’s-like conditions in rodent models (Beal, 2010).  In addition, the mitochondrial 
toxin 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) was shown to be responsible 
for the onset of severe Parkinson’s-like symptoms in a group of young drug users in the 
1980s (Fahn, 1996).  Drugs such as rotenone, paraquat, and MPTP disrupt normal 

































generation. Through the generation of ROS, environmental exposure to mitochondria-
damaging toxins may be important in the pathogenesis of Parkinson’s disease in rare 
cases.  Additionally, these findings suggest that the deregulation of oxidative stress may 
be important for the pathogenesis of all forms of Parkinson’s disease, even without the 
environmental toxin exposure. Mitochondrial dysfunction has been linked to Parkinson’s 
disease in the past few decades and recent genetic evidence indicating mitochondrial 
involvement in this disease has underscored this relationship. For example, genes such as 
PINK1 and HTRA2 have recently been associated with familial Parkinson’s disease and 
are proposed to be key modulators of mitochondrial molecular quality control. 
 
Mitochondria dysfunction and Parkinson’s disease pathology 
 
Mitochondria are the powerhouses of eukaryotic cells and are responsible for 
most of the ATP synthesis via oxidative phosphorylation (OXPHOS). During OXPHOS, 
NADH, and FADH2 produced by glycolysis and the tricarboxylic acid (TCA) cycle are 
used as electron donors and transported through the electron transport chain (ETC) via a 
series of redox reactions that involve four molecular complexes (Complexes I, II, III, and 
IV). Oxygen is used as the final electron acceptor and is reduced to water through the 
acquisition of four electrons. The transport of electrons through the ETC is coupled to the 
discharge of protons from the mitochondrial matrix to the intermembrane space. The 
discharge of protons leads to the generation of a proton gradient that is necessary for the 
synthesis of ATP from ADP by ATP synthase. During transport through the ETC, a small 
portion of electrons escape prematurely and directly reduce oxygen, generating the 
superoxide anion (O2
•−
) (Fig. 4).  These ROS can interact with other molecules to form 
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other types of ROS, such as hydrogen peroxide (H2O2) and the hydroxyl radical (OH
•
). In 
addition to the physiological ROS produced by normal mitochondrial activity, 
nonphysiological increases in ROS levels can occur in conditions of stress, such as 
nutrient deprivation or hypoxia, or as a consequence of the deterioration of mitochondrial 
enzymes (Desideri et al, 2012). 
The increase in ROS concentration, a condition known as oxidative stress, can be 
detrimental for the mitochondria and the entire cell because of the capacity of ROS to 
damage several cellular components, including proteins, lipids, and nucleic acids. To 
cope with the detrimental effects of ROS under normal conditions, cells are equipped 
with several antioxidant systems that comprise a first line of defense against these toxic 
agents.  One of the mitochondrial antioxidant defense pathways is the thioredoxin-2 
(Trx2) system, formed by Trx2 and thioredoxin reductase 2 (TrxR2), and peroxiredoxin-3 
(Prx3); both are involved in the scavenging of hydrogen peroxide (Tanaka et al, 2002).  
The other major endogenous cellular antioxidant system is the glutathione 
peroxidase/glutathione reductase system.  The biochemical function of glutathione 
peroxidase is to reduce hydrogen peroxide to water: 2GSH + H2O2 → GS–SG + 2H2O 
(Ran et al, 2007).  If any component in either of these major antioxidant pathways is 
disrupted through genetic or environmental factors, the result will be a deregulation of the 
cellular redox equilibrium and a buildup of toxic ROS.  The buildup of oxidative stress is 
especially toxic to dopamine neurons and elevated oxidative stress is one of the main 






Figure 4: Mitochondrial Electron Transport Chain 
Electron transport chains are the major sites of premature electron leakage to oxygen 
resulting in cellular oxidative stress.  A build-up of reactive oxygen species can be toxic 
to dopamine neurons and can cause Parkinson’s disease.  In healthy cells, there are a 
number of functional anti-oxidant pathways to reduce oxidative stress (Huang T.T., et. al. 
(2006). Genetic modifiers of the phenotype of mice deficient in mitochondrial superoxide 






Genetics of Parkinson’s disease 
An important advance in Parkinson’s disease research came when the first genetic 
cause of disease was discovered in 1997.  Since this finding, genetic research in 
Parkinson’s disease has led to the identification of several monogenic forms of the 
disorder as well as numerous genetic factors that increase the risk of developing 
Parkinson’s disease.  Even with the recent findings, it is still currently thought that only 
between 10-15% of cases are genetic. However, the increased understanding of 
Parkinson’s disease genetics has brought tremendous insight into the pathogenesis of 
genetic as well as non genetic cases of Parkinson’s disease.  Genetic research has been 
the driving force behind treatment breakthroughs that will eventually benefit everyone 
with Parkinson’s disease.  Table 1 is a list of current genes associated with familial 
Parkinson’s disease; it is followed by detailed descriptions of insights that the discoveries 
of each of these genes has provided for the understanding of disease pathogenesis.  
SNCA 
Genetic markers on human chromosome 4q21-q23 segregated with Parkinson’s 
disease phenotype on a large Italian American kindred presenting with autosomal 
dominant familial Parkinson’s.  The family presented with clinically typical phenotype 
with the exception of the early age of onset, on average 46 ± 13 years of age, compared to 
59 ± 11 years of age in sporadic cases (Payami et al., 1995; Polymeropoulos et al, 1996).  
Traditional genotype analysis of the kindred and sequence analysis of candidate genes 
within the genetic loci revealed a mutation in the SNCA gene.  The causative missense 
mutation in this family was a single base pair change at position 209 from Guanine to 
Adenine, G209A.  The single nucleotide polymorphism resulted in an Alanine to  
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Table 1: Genetics of Parkinson’s disease 
Gene Loci Chromoso
me 
Gene  Inheritance OMIM 
PARK1 4q21 SNCA (the α-synuclein gene) AD 168601 
PARK2 6q25.2-27 PARK2 (the Parkin gene) AR 600116 
PARK3 2p13  AD 602404 
PARK4 4q21 SNCA (the α-synuclein gene) AD 605543 
PARK5 4p14 UCHL1 (the ubiquitin 
carboxyl-terminal esterase L1 
gene) 
AD 613643 
PARK6 1p36 PINK1 (the PTEN-induced 
putative kinase 1 gene) 
AR 605909 
PARK7 1p36 DJ-1 AR 606324 
PARK8 12q12 LRRK2 (the leucine-rich 
repeat kinase 2 gene) 
AD 607060 
PARK9 1p36 ATP13A2 (the ATPase type 
13A2 gene) 
AR 606693 
PARK10 1p32  Late Onset 606852 
PARK11 2q37.1 GIGYF2 (the GRB10 
interacting GYF protein 2 
gene) 
AD 607688 
PARK12 Xq21-q25  X-linked 300557 
PARK13 2p12 HTRA2 (the Htra serine 
peptidase 2 gene) 
AD 610297 
PARK14 22q13.1 PLA2G6 (the phospholipase 
A2 group VI gene) 
AR 612953 
PARK15 22q12-q13 FBX07 (the F-box only 
protein 7 gene) 
AR 260300 
PARK16 1q32   613164 
PARK17 16q11.2 VPS35 (the vacuolar protein 
sorting 35 gene) 
AD 614203 
PARK18 3q27.1 EIF4G1 (the eukaryotic 
translation initiation factor 4 
gamma gene) 
AD 614251 
Risk Loci 1q21 GBA (the glucosidase beta 
acid gene) 






Threonine substitution at amino acid position 53, A53T, in the α-synuclein protein.  The 
G209A point mutation and subsequent A53T substitution was found to be present in three 
unrelated Greek families and segregated with early-onset Parkinson’s disease phenotype 
in these families (Polymeropoulos et al, 1997).   
The rare gene mutation found in these few families raised questions whether the 
rare inherited forms of Parkinson’s disease were pathologically unrelated to common 
sporadic forms: whether the two were simply unrelated disorders that happened to present 
with similar phenotype.  However, soon after, researchers showed that α-synuclein was 
the major component in Lewy bodies (Spillantini et al, 1997).  Lewy bodies are abnormal 
aggregates of protein that develop inside dying dopamine neurons in all patients with 
Parkinson’s disease; Lewy bodies are a pathological hallmark of Parkinson’s disease 
(Fig. 5).  This work elegantly linked familial and sporadic forms of Parkinson’s disease 
and revealed for the first time that abnormal protein catabolism was a critical step in the 
pathogenesis of all cases of Parkinson’s disease.  
To date there have been two disease-causing missense mutations identified in α-
synuclein in addition to the A53T mutation.  The A30P mutation was identified in a 
German Parkinson’s disease family and the E46K mutation was identified in a Spanish 
Parkinson’s disease family (Kruger et al, 1998; Zarranz et al, 2004).  In addition to the 
discovery of missense mutations in SNCA, duplication of the SNCA gene was identified 
as the cause of disease in a family presenting with early-onset (between 39-60 years) 
autosomal dominant disease.  Affected individuals in this family had a duplication event 
on one chromosome resulting in a total of three normal copies of SCNA being expressed 
(Chartier-Harlin et al, 2004).  Additionally, a family presenting with very early onset 
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Parkinson’s, mean age of 34 years, has been identified in which affected individuals have 
two extra—but otherwise normal—copies of the SNCA gene resulting in double the 
amount of α-synuclein protein (Singleton et al, 2003).  The onset of disease and co-
occurrence of dementia appear to be associated with the number of copies of SNCA.  This 
finding has led to the hypothesis of a dose relationship between α-synuclein levels and 
disease severity (Singleton et al, 2004).   The hypothesis can be further extended to a 
theory of dysfunctional protein catabolism resulting in a build-up of proteins, including 
α-synuclein, as a cause of late-onset sporadic forms of Parkinson’s disease. 
  
Figure 5: α-Synuclein is the main component of Lewy bodies in all cases of 
Parkinson’s disease Substantia nigra from patients with Parkinson’s disease 
immunostained for α-synuclein.  Arrow shows α-synuclein staining within a pigmented 
dopamine neuron cell body.  The α-synuclein protein aggregates form an intercellular 
structure called a Lewy body in all patients with Parkinson’s disease. This research was 
originally published in Journal of Biological Chemisrty. Zhou W., Bercury K., 
Cummiskey J., Luong N., Lebin J., Freed C.R., Phenylbutyrate Up-regulates the DJ-1 
Protein and Protects Neurons in Cell Culture and in Animal Models of Parkinson 
Disease.  JBC. 2011; 289(17):14941-14951. © the American Society for Biochemistry 






The PARK2 gene was first reported to be associated with autosomal recessive 
juvenile Parkinson’s disease (AR-JP) in 1998.  Researchers linked AR-JP to the    
6q25.2-q27 region of the genome and described a homozygous deletion of exons 3-7 of 
the PARK2 gene in one Japanese AR-JP patient.  The researchers named the previously 
undescribed protein product ‘Parkin’ (Kitada et al, 1998).  Since this discovery, a number 
of small and large deletions as well as point mutations have been identified in PARK2 
that are thought to account for up to 10% of early-onset Parkinson’s cases.  The clinical 
phenotypes of homozygous or compound heterozygous PARK2 cases are usually 
indistinguishable from early-onset idiopathic Parkinson’s disease.   
Parkin is a ligase component of a multiprotein E3-Ubiquitin Ligase complex.  The 
normal function of this complex is to mediate the targeting of proteins for degradation by 
the Ubiquitin Proteosome System (UPS).  Pten-induced kinase I (Pink1), the 
mitochondrial protein product of the PARK6 gene and DJ-1, the protein product of 
PARK7 are also known to be part of this complex (Fig 6).  Parkin ligase is responsible for 
the ligation of ubiquitin protein onto misfolded or otherwise unneeded proteins targeting 
them for degradation by the proteasome.  Parkin ligase has been shown to interact with a 
number of cellular proteins targeting them for degradation.  Most importantly, studies 
have shown that Parkin readily binds to α-synuclein in vitro and the two proteins are co-
localized in the postmortem brain of Parkinson’s patients as well as normal controls 
(Choi et. al., 2001).  Additionally, induced pluripotent stem cell (iPSC)-derived neurons 
generated from patients with PARK2 mutations contain significant levels of abnormal    
α-synuclein accumulation (Imaizumi et al, 2012).  These findings suggest that normal 
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Parkin functions include targeting α-synuclein for degradation and that loss of Parkin 
function results in toxic α-synuclein aggregation, dopamine cell death and early onset 
Parkinson’s disease.  
PINK1 
Mutations in the PARK6 gene were first reported to be associated with early-onset 
Parkinson’s disease in 2004.  Researchers reported a homozygous nonsense mutation in 
two Italian families and a homozygous missense mutation in a Spanish family (Valente et 
al, 2004).  Mutations in PTEN-induced kinase 1 (Pink1), the protein product of PARK6, 
are loss of function mutations that have been found to be the second most common cause 
of early-onset autosomal recessive Parkinson’s disease, next to mutations in Parkin. 
 
Figure 6: Parkin, Pink1 and DJ-1 interact in a multiprotein E3 Ubiquitin Ligase 
complex 
Loss of function of this complex—due to mutations in any of these three components—
prevents proper degradation of proteins that can be toxic to dopamine neurons.  One of 
the proteins known to be a target of this complex is α-synuclein, the main component of 

































Although the exact function of Pink1 is unknown, the protein is known to interact 
with Parkin and DJ-1 in the multiprotein E3 Ubiquitin ligase complex responsible for the 
targeted degradation of proteins in the cell (Fig 6).  Additionally, recent reports suggest 
that Pink1 works upstream of Parkin in the same pathway to regulate mitochondrial 
homeostasis and conduct autophagic clearance of damaged mitochondrial proteins 
(Matsui et al, 2013).  These studies suggest that the normal function of Pink1 is crucial 
for healthy mitochondrial function and that loss of Pink1 function mutations result in loss 
of mitochondrial homeostasis.  Loss of mitochondrial homeostasis causes unregulated 
cellular oxidative stress and formation of toxic cellular protein aggregation; both of 
which can cause neuronal death and early-onset Parkinson’s disease.   
DJ-1 
The DJ-1 gene is located on chromosome region 1p36 and encodes a small, 
highly conserved 189 amino-acid protein.  DJ-1 is a ubiquitously expressed protein that 
was first identified as an oncogene (Nagakubo et al, 1997).  DJ-1 has since been reported 
to be involved in breast cancer, lung cancer and prostate cancer (Le Naour et al, 2001; 
Miura et al, 2002; Grzmil et al, 2004).  DJ-1 is also named CAP-1 (contraception 
associated protein 1) and was identified as the target of some environmental toxicants 
that lead to male infertility (Wagenfeld et al, 1998).  A homolog of DJ-1, the YajL gene, 
was first expressed in aerobic bacteria.  The gene YajL is the closest prokaryotic homolog 
of the human DJ-1 gene with 40% genetic sequence identity and a nearly identical three-
dimensional structure; YajL requires dimerization to function. When a mutant form of 
YajL that prevents dimerization is expressed in Escherichia coli, the bacteria display an 
increased sensitivity to oxidative stress and protein aggregation (Kthiri et al, 2010).  
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Homologs of human DJ-1 have been essential to cellular protection as far back in 
evolutionary time as aerobic prokaryotes. 
The original mapping study that linked Parkinson’s disease to the PARK7 locus 
was part of a program called “Genetic Research in Isolated Populations” or GRIP.   As 
part of this research program, investigators studied a family with an autosomal recessive 
form of early-onset Parkinson’s disease characterized by development of symptoms 
before the age of 50.  This family was from an isolated population in the southwestern 
region of the Netherlands; the family had multiple consanguinity loops (Fig. 7).  
Systematic screening of transcripts within the novel PARK7 locus from affected 
individuals compared with healthy controls delineated the DJ-1 gene as the gene 
associated with disease in this family.  The causal mutation was identified as a deletion 
spanning five exons of DJ-1 resulting in the translation and subsequent degradation of a 
severely truncated DJ-1 protein (Bonifati et al, 2003).  The PARK7 locus was confirmed 
by an additional causal mutation in DJ-1 found in an Italian family presenting with 
autosomal recessive early-onset Parkinson’s disease (Miller et al, 2003).  The second 
mutation found was a homozygous missense mutation replacing a lysine at residue 166 
with a proline residue, L166P.  The substitution is in a highly conserved region of the 
protein and prevents proper dimerization of DJ-1 (Fig. 8) 
DJ-1 is known to function as a homodimer and its three dimensional structure is 
known (Honbou et al, 2003; Lee et al, 2003; Tao et al, 2003; Wilson et al, 2003).  The 
crystal structure shows a compact globular domain with an active site catalytic triad of 
glutamate at residue 18, cysteine at residue 106 and histamine at residue 126 (Fig. 8).  In 
the presence of ROS, the thiol side chain on cysteine residue 106 is oxidized and the DJ-1 
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protein shifts to a variant with a more acidic pI—from 6.7 in physiological conditions to 
5.8 in the oxidative stress conditions.  The change in pI of DJ-1 is irreversible and DJ-1 is 
thought to be an essential indicator for cellular oxidative stress (Mitsumoto et al, 2001). 
Using solution state NMR and circular dichroism spectroscopies, investigators showed 
that the L166P mutation leads to severe and global destabilization and unfolding of the 
protein structure (Malgieri et al, 2008).  Unstable DJ-1 monomers are degraded through 
the ubiquitin-proteasome pathway resulting in depleted protein levels and functionally 
mimicking the deletion mutation resulting in low or absent DJ-1 protein (Miller et al, 
2003).  In addition to the L166P causal missence mutation described in Bonfanti et al, 
more than ten mutations in DJ-1 have been associated with familial Parkinson’s disease.  
These mutations include missense, truncation and splice-site mutations that act as 
deletions in the gene suggesting that loss-of-function of DJ-1 results in 
neurodegeneration (Clark et al, 2004).  
Since loss-of-function mutations in DJ-1 result in neurodegeneration, it is 
resonable to hypothesize that neuronal protection is a normal function of the DJ-1 
protein.  Prior to my thesis work, in vitro studies were done by our group to initially 
elucidate the major mechanisms of protection utilized by DJ-1.  Briefly, the DJ-1 gene 
was overexpressed in a rat dopaminergic cell line (N27 cells) and then the cells were 






Figure 7: Pedigree of a Dutch family with autosomal recessive early-onset 
Parkinson’s disease 
Individuals VI-2, VI-3 and VII1-VII7 were examined by the GRIP researchers.  Black 
diamonds indicate affected individuals; black bars indicate the disease causing 
phenotype.  Reprinted from American Journal of Human Genetics, 69/3, van Duijn C.M., 
Dekker M.C., Bonifati V., Galjaard R.J., Houwing-Duisermaat J.J., Snijders P.J., Testers 
L., Breedveld G.J., Horstink M., Sandkuijl L.A., van Swieten J.C., Oostra B.A., Heutink 
P, Park7, a novel locus for autosomal recessive early-onset parkinsonism, on 





Figure 8: Crystal structure of human DJ-1 dimer 
In solution and under normal physiological conditions, DJ-1 forms a stable dimer which 
is biologically active.  This figure shows the crystal structure model of dimeric human 
DJ-1 with the known mutation sites indicated with *.  This research was originally 
published in Journal of Biological Chemisrty. Bjorkblom B., Adilbayeva A., Maple-
Grodem J., Piston D., Okvist M., Xu X.M., Brede C., Larsen J.P., Moller S.G., Parkinson 
Disease Protein DJ-1 Binds Metals and Protects against Metal-induced Cytotoxicity.  
JBC. 2013; 288(31):22809-22820. © the American Society for Biochemistry and 
Molecular Biology. 
 
Results showed that the overexpression of wild-type DJ-1 in N27 cells was 
sufficient to protect the dopamine neurons from cell death caused by hydrogen peroxide.  
Additionally, overexpression of wild-type DJ-1 was able to protect N27 cells from cell 
death caused by co-transfection with a mutant form of α-synuclein that readily forms 
aggregates (A53T mutant α-synuclein).  By contrast, knocking down the endogenous 
levels of DJ-1 in N27 dopamine cells with antisense DJ-1 rendered cells more sensitive to 
both hydrogen peroxide treatment and A53T mutant α-synuclein transfection.  The 
L166P mutant form of DJ-1, which causes early-onset Parkinson’s disease in humans, 




the in vitro experiments show that N27 cells overexpressing the L166P mutant DJ-1 had 
no protection against hydrogen peroxide or A53T mutant α-synuclein.  
The preliminary findings from our group revealed that DJ-1 is sufficient to protect 
dopamine neurons in culture from separate, specific cellular stresses by selectively up-
regulating appropriate protection mechanisms.  DJ-1 decreases cellular sensitivity to 
oxidative stress by specifically increasing cellular glutathione (GSH) levels through up-
regulating the rate-limiting enzyme glutamate cysteine ligase (GCL). When endogenous 
DJ-1 is knocked down with antisense DJ-1, the GSH pathway is not activated.  The GSH 
oxidative stress response pathway is one of the essential intrinsic cellular protection 
mechanisms.  DJ-1 can detect oxidative stress in cells and can specifically up-regulate the 
GSH pathway for protection against toxicity (Fig. 9). Furthermore, DJ-1 decreases cell 
death caused by transfection of A53T mutant α-synuclein by increasing the cellular levels 
of chaperone protein Heat shock protein 70 (Hsp70).  When exposed to cellular stress 
caused by abnormal protein aggregation, DJ-1 specifically up-regulated Hsp70, but did 
not up-regulate the GSH levels.  Again, when endogenous levels of DJ-1 were knocked 
down with antisense DJ-1, the levels of Hsp70 remained un-changed and the cellular 
protection from A53T mutant α-synuclein was abolished (Fig. 9). 
Both oxidative stress and abnormal α-synuclein aggregation have been implicated 
in the pathogenesis of Parkinson’s disease.  The previous in vitro studies done by our 
group have revealed the critical role that DJ-1 plays in protecting dopamine neurons from 
oxidative stress and A53T mutant α-synuclein aggregation and toxicity (this work is 
described in detail in Zhou et. al., 2005).  These preliminary results have paved the way 
for my thesis research in which I explore in-depth the molecular mechanisms of 
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protection of DJ-1.  Additionally, I study pharmacological and environmental exercise 
therapies aimed at up-regulation of the DJ-1 gene and protein in animal models and in 
patients with Parkinson’s disease.  The end goal of my research is to find therapies that 
change DJ-1 gene expression in order to prevent dopamine neuron death and stop the 
progression of Parkinson’s disease.   
 
 
Figure 9:  Mechanism by which DJ-1 protects dopamine neurons against oxidative 
stress and A53T α-synuclein toxicity 
Overexpression of human WT DJ-1 increases total cellular DJ-1 levels; by contrast, AS 
DJ-1 treatment reduces total levels of endogenous cellular DJ-1 resulting in DJ-1 knock-
down.  During oxidative stress, DJ-1 specifically enhances GCL expression.  The 
increased GCL mRNA and GCL enzymatic activity lead to increased GSH levels that 
reduce apoptosis caused by oxidative stress.  When the cells are exposed to mutant A53T 
α-synuclein protein, DJ-1 specifically enhances Hsp70 mRNA expression and protein 
levels without changing GSH levels.  The molecular chaperone protein Hsp70 prevents 
formation of α-synuclein aggregates and reduces cellular toxicity This research was 
originally published in Journal of Biological Chemisrty. Zhou W., Freed C.R., DJ-1 up-
regulates glutathione synthesis during oxidative stress and inhibits A53T alpha-synuclein 
toxicity.  JBC. 2005; 280(52): 43150-43158.  © the American Society for Biochemistry 







Linkage of autosomal dominant Parkinson’s disease to the PARK8 locus in a 
region of chromosome 12 was reported in 2002 by researchers investigating a large 
Japanese family (Funayama et al, 2002). The underlying genetic cause of chromosome 
12-linked Parkinson’s disease was reported to be a mutation in the LRRK2 gene; 
mutations in this gene result in autosomal dominant forms of Parkinson’s disease 
(Zimprich et al, 2004). Current predictions are that LRRK2 mutations account for 5-13% 
of familial Parkinson’s cases and 1-5% of those previously considered as being sporadic 
(Berg et al, 2005).  A large number of mutations in LRRK2 have since been reported and 
proposed as causal, however only a handful have been supported with a high degree of 
proof  based on overwhelming association or disease segregation data.  A total of five 
mutations in LRRK2 have been reported with high degree of evidence to be causal in 
families: R1441G, R1444C, Y1699C, I2020T and G2019S (Paisan-Ruiz et al, 2004; 
Zimprich et al, 2004; Gilks et al, 2005).  The highly variable penetrance of LRRK2 
mutations is responsible for the lack of convincing genotype-to-phenotype data for this 
gene.  There are likely several factors that influence penetrance and expressivity of 
LRRK2 mutations, including genetic co-factors and external and environmental factors 
(Fig 10). 
 Although the normal function of the Lrrk2 protein remains unclear, it has been 
implicated in a number of cellular processes including cytoskeletal dynamics, 
endocytosis, autophagy and vesicle trafficking.  It has been proposed that Lrrk2 
positively regulates autophagy under normal conditions.  Lrrk2 has been shown to 
activate the calcium-dependent protein kinase β (CaMPK-β)/adenosine monophosphate 
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(AMP)-activated protein kinase (AMPK) pathway (Gomez-Suaga et. al., 2012).  This 
kinase pathway activates the formation of autophagosomes, the organelles that sequester 
cellular debris through vesicle trafficking and then fuse with lysosomes, where 
degradation occurs. Further support of this premise is that the common LRRK2 mutation 
G2019S is associated with accumulation of autophagic vesicles and dopaminergic cell 
death in transgenic mice expressing the mutation (Ramonet et al, 2011).  Further 
evidence that LRRK2 mutations result in insufficient vesicle trafficking is the recent 
finding that LRRK2 interacts with the cytoskeletal component F-actin.  The cytoskeleton 
in nerves is essential for normal vesicle transport along the nerve and ultimately for 
communication between nerves.  Mutations in LRRK2 have been shown to disrupt the 
interaction with F-actin (Meixner et al, 2011).  Gain of function mutations in LRRK2 can 
result in a variety of phenotypes, but disruption in proper vesicle trafficking seems to be 
the major mechanism of pathogenesis (Fig. 10).   
 
 
Figure 10: Lrrk2 function and disease pathogenesis 
The exact functions of Lrrk2 are still largely unknown, but it is thought to be a kinase 
involved in proper vesicle trafficking and maintenance of cytoskeletal dynamics.  LRRK2 















In 2008, researchers investigated the possible genetic cause of autosomal 
recessive early-onset Parkinson’s disease in a large consanguineous Iranian family.   The 
affected individuals in this family developed symptoms in the late teens and also 
presented with pyramidal tract signs, defined by spasticity and increased threshold of 
superficial reflexes.  This rare set of symptoms is known as Parkinsonian Pyramidal 
Disease (PPD).  Using genome-wide linkage analysis, the researchers identified the 
PARK15 locus on chromosome 22.  They identified the disease causing mutation was a 
homozygous missense mutation in the F-Box protein 7 (FBX07) (Shojaee et al, 2008).  
Although few cases and families are affected by PPD and mutations in the FBX07 gene 
are rare, understanding the pathological mechanisms of FBX07 mutations should provide 
important insights into pathogenesis of all forms of Parkinson’s disease. 
Little is known about the FBX07 protein; however there have been some co-
immunoprecipitation studies that describe the general cellular pathways the protein is 
involved in. The FBX07 protein belongs to the F-Box-containing protein group, which is 
one of four subunits of the ubiquitin protein ligase complex called the Skp-1-Cullin-F-
Box complex (Ilyin et al, 2000).  Although the function of FBX07 within this complex is 
not yet understood, the ubiquitin-mediated protein degradation system (UPS) has 
previously been implicated to play an important role in the pathogenesis of 
neurodegenerative diseases.  The rare FBX07 mutations that have been discovered 
emphasize the importance of further investigating the UPS pathway in the pathogenesis 





Gaucher’s disease is a genetic disease in which affected individuals accumulate 
lipids within their cells due to lysosomal dysfunction.  Keen clinical observations 
revealed that patients and relatives of patients with Gaucher’s disease present with a 
higher incidence of Parkinson’s disease compared to the general population (Williams et 
al, 2006).  This finding ultimately led to the identification of mutations in GBA as a risk 
factor for Parkinson’s disease.  The initial report of a strong association between single 
GBA mutations and Parkinson’s disease was published in 2004.  The report revealed that 
within the Ashkenazi Jewish population, a mutation in the GBA gene was associated with 
a ~sevenfold increased risk of Parkinson’s disease (Aharon-Peretz et al, 2004).  In the 
years following the initial report, a large meta-analysis of existing GBA mutation data 
was performed.  This analysis conclusively demonstrated that carriers of a single GBA 
mutant allele were at ~fivefold greater risk for Parkinson’s disease compared to 
individuals without a GBA mutant allele (Sidransky et al, 2009).   
Gaucher’s disease is the most common lysosomal storage disorder and is caused 
by an inherited loss of function of the lysosomal enzyme glucocerebrosidase, encoded by 
the GBA gene.  The normal function of the enzyme is to metabolize the fatty acid 
glucosylceramide inside the lysosome.  When the enzyme is defective, glucosylceramide 
accumulates within the lysosomes and eventually shuts down lysosome function.   One of 
the hallmarks of Parkinson’s disease is the accumulation of α-synuclein protein fibrils 
within Lewy body inclusions.  Under normal conditions, neurons quickly recognize and 
degrade α-synuclein aggregates before they form toxic fibrils using both the ubiquitin-
proteasome system and the autophagy-lysosome degradation pathway.  Mutations in GBA 
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result in accumulation of phospholipids in lysosomes and eventual loss of function of the 
autophagy-lysosome degradation and the ability of the cell to degrade α-synuclein as it 
forms aggregates.  In time, α-synuclein fibrils form toxic Lewy body inclusions, cause 
neuronal cell death and Parkinson’s disease.  
Objective 
 
The practical goal of my thesis research is to identify new methods of therapy 
aimed at preventing further neurodegeneration and stopping the relentless progression of 
Parkinson’s disease.  The current gold standard of care for Parkinson’s disease is 
treatment with dopamine precursors which only temporarily alleviate the motor 
symptoms, but do nothing to prevent further neuronal death.  Therefore, the disease will 
continue to progress in patients taking dopamine precursors alone.  My research approach 
is to target and up-regulate the neuroprotection gene DJ-1 and activate protection 
pathways in order to clear toxic cellular stresses from the remaining dopamine neurons in 
Parkinson’s patients and halt the progression of disease.  Studies done prior to my thesis 
research revealed that DJ-1 is able to activate oxidative stress response pathways when 
cells are exposed to reactive oxygen species toxins.  Separately, DJ-1 is able to up-
regulate chaperone proteins when cells are exposed to protein aggregate toxins.  From 
these preliminary findings I formulated the following hypothesis:  Since DJ-1 is 
neuroprotective, any therapy that could up-regulate DJ-1 without being harmful to cells 
could activate neuroprotection pathways in dopamine neurons in Parkinson’s patients 
thereby preventing future neuronal death and stopping the progression of disease. 
To test my thesis hypothesis, I separated my research into three main objectives.  
In Chapter II, I detail the rationale, experiments and results of my first objective.  The 
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first objective was to discover a small molecule drug that could up-regulate DJ-1 
expression and to test whether treatment with the drug could prevent the age-dependent 
disease development our transgenic mouse model of diffuse Lewy body disease.  First, a 
number of small molecule HDAC inhibitors were screened in vitro for their ability to up-
regulate DJ-1expression.  I found that the FDA-approved drug sodium phenylbutyrate, 
which will henceforth be referred to as phenylbutyrate, was able to significantly up-
regulate DJ-1 in dopamine neurons in culture.  Next, I investigated whether 
phenylbutyrate treatment could rescue the phenotype of a transgenic mouse model of 
diffuse Lewy body disease.  Results from my first objective show that treatment with 
phenylbutyrate for three months was sufficient to prevent disease progression in the 
transgenic mice.  Phenylbutyrate treatment up-regulated brain DJ-1 levels, prevented the 
motor and cognitive decline, and reduced the α-synuclein oligomer formation in the 
brains of transgenic animals.    
Based on the exciting results from my first research objective, my next objective 
was to investigate the detailed cellular mechanisms by which phenylbutyrate treatment 
and subsequent DJ-1 up-regulation were able to protect dopamine neurons from death 
and prevent disease development in the transgenic animals.  The experiments performed 
to achieve the results for my second objective are detailed in Chapter III and Chapter IV.  
The results from Chapter III reveal that the reduction in brain α-synuclein oligomers 
observed in the transgenic mice that were treated with phenylbutyrate were the result of a 
drug-induced activation of protein mobilization pathways from the brain to the blood.  
Results from cell culture, transgenic mice and human Phase I clinical trials show that 
there is a natural mechanism of clearance of α-synuclein from brain to plasma and that 
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treatment with phenylbutyrate can enhance the clearance mechanism.  Next, as described 
in Chapter IV, I performed an extensive gene expression screen of distinct cellular 
pathways to better understand the mechanisms of action of phenylbutyrate treatment and 
DJ-1 up-regulation.  Results from this differential expression screen reveal that treatment 
with phenylbutyrate increases DJ-1 gene expression and protein levels.  Up-regulation of 
DJ-1 will activate the specific oxidative stress protection pathways in order to protect 
cells from hydrogen peroxide toxicity.  Through separate mechanisms of action, DJ-1 
will activate protein catabolism pathways in order to protect cells from abnormal            
α-synuclein aggregate toxins.  Importantly, these findings reveal that healthy neurons 
utilize the lysosome/exosome protein catabolism pathway in order to eliminate toxic      
α-synuclein oligomers from dopamine neurons.  Results suggest that the efficiency of 
lysosome/exosome elimination is reduced in Parkinson’s patients resulting in the build-up 
of α-synuclein aggregates as Lewy bodies in the cells.  We found that phenylbutyrate 
treatment and up-regulation of DJ-1 may activate the α-synuclein oligomer elimination 










In 2003 a loss-of-function mutation in the DJ-1 protein was associated with early-
onset autosomal recessive Parkinson’s disease (Bonifat et al, 2003).  Because low levels 
of DJ-1 cause Parkinson’s disease, it is reasonable to hypothesize that overexpression of 
DJ-1 might stop disease progression.  Up-regulation of neuroprotective gene DJ-1 
protects neurons from both pathological hallmarks of Parkinson’s disease: increased 
intracellular oxidative stress and increased intracellular protein aggregates.  First, under 
oxidative stress conditions, DJ-1 protein levels positively correlate with GCL expression 
levels and enzymatic activity.  GCL is the rate limiting step in GSH synthesis; therefore, 
increases in GCL activity result in increases in intracellular GSH and reduced 
intercellular reactive oxidative species.  Second, under conditions of abnormal α-
synuclein aggregation, DJ-1 protein levels positively correlate with Hsp70 mRNA and 
protein levels (Zhou et al, 2005). The chaperone protein Hsp70 protects dopamine 
neurons against toxicity of α-synuclein aggregation.  Hsp70 promotes degradation of 
misfolded α-synuclein by the proteasome (Donmez et al, 2012).  Elevated levels of DJ-1 
activate specific pathways of neuorprotection and reduced levels of DJ-1 cause 
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 Parts have been reproduced with permission from Journal of Biological Chemisrty. 
Zhou W., Bercury K., Cummiskey J., Luong N., Lebin J., Freed C.R., Phenylbutyrate Up-
regulates the DJ-1 Protein and Protects Neurons in Cell Culture and in Animal Models of 
Parkinson Disease.  JBC. 2011; 289(17):14941-14951. © the American Society for 




Parkinson’s disease. Therefore, a pharmacological therapy that up-regulates DJ-1 levels 
would prevent dopamine cell death and stop progression of Parkinson’s disease.   
Small molecule histone deacetylase inhibitors have shown promising results for 
prevention of progression of a number of neurodegenerative disorders.  After screening a 
number of small molecules, we have found that the histone deacetylase inhibitor 
phenylbutyrate increases DJ-1 expression by 300% in the N27 dopamine cell line and 
rescues cells from oxidative stress and mutant α-synuclein toxicity. In a transgenic mouse 
model of diffuse Lewy body disease, long-term administration of phenylbutyrate reduces 
α-synuclein aggregation in brain and prevents age-related deterioration in motor and 
cognitive function. These findings indicate that the drug phenylbutyrate is a promising 
therapy to up-regulate DJ-1 gene expression that slow the progression of Parkinson 
disease by moderating oxidative stress and protein aggregation. 
 
Study design and methods 
Culture of N27 cells and treatment with HDAC inhibitors 
Dopaminergic cells derived from embryonic day 12 rat mesencephalon and 
immortalized with the SV40 large T antigen designated 1RB3AN27 (N27 cells) were 
used (Adams et al., 2006). N27 cells were cultured in 6-well plates in RPMI 1640 
medium containing 10% fetal bovine serum.  Cells were treated with sodium 
phenylbutyrate (PB, from Scandinavian Formulas) at a concentration of 100μM for 48 
hours, followed by exposure to a cellular toxin for 24 hours.  Cells were either exposed to 
oxidative stress toxin; to expose cells H2O2 at a final concentration of 100μM was mixed 
with culture medium and incubated with cells for 24 hours.  Cells were also exposed to 
an A53T α-synuclein adenovirus transduction; to transduce cells, A53T α-synuclein 
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adenovirus was mixed with culture medium at a concentration of 200 plaque forming 
units (pfu) / cell and incubated for 24 hours.   
MTT assay and apoptosis evaluation 
At the end of each experiment, methylthiazoletetrazolium (MTT) was added to 
the culture medium (final concentration 0.4 mg/ml) and incubated for 2 h. Cell viability 
was measured by a microplate reader. The nuclear dye Hoechst 33258 (10 μg/ml) was 
used to visualize and count apoptotic cells. 
Western blotting 
N27 cells were cultured in 6-well plates and treated with compounds as described 
above.  Cells were lysed in a dissociation buffer containing 50 mM Tris-HCl, 10 mM 
NaCl, 0.1% Triton X-100 plus protease inhibitor mixture (Roche).  Protein concentration 
PAGE pre-case gel (BioRad) and transferred to a nitrocellulose membrane. After 
blocking nonspecific binding, membranes were incubated with antibodies to DJ-1 
(1:1000, Millipore) and β-actin (1:2000, Sigma).  Blots were incubated with HRP-
conjugated secondary antibody (1:10,000, Jackson Immuno Research), followed by 
chemiluminescent detection (Perkin Elmer Life Sciences). 
Phenylbutyrate treatment in α-synuclein transgenic mice 
All animal procedures were approved by the Institutional Animal Care and Use 
Committee (IACUC) at the University of Colorado Denver.  Our Y39C human α-
synuclein transgenic mouse model has been described (Zhou et al, 2008).  Briefly, human 
Y39C α-synuclein cDNA was cloned into the mouse pThy-1 vector at the NotI site.  The 
construct was micro injected into mouse oocytes and founder mice were identified by 
PCR and Southern blotting analysis.  Mice were bred to establish stable transgenic lines. 
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Expression of human Y39C α-synuclein in these transgenic mice was determined by 
immunostaining and Western blotting with antibodies specific to human α-synuclein.   
Adult Y39C α-synuclein transgenic mice (4–6 months old) were treated with 
phenylbutyrate in drinking water for 14 days in the initial screen and then for 12 weeks 
for analysis of phenotype development. The phenylbutyrate was dissolved in water at 
concentrations of 500, 1000, 1500, and 2000 mg/liter for the drug screen. Mice typically 
drink 4–5 ml of water per day, and their drinking volumes were not affected by the 
addition of phenylbutyrate. During the 12 week drug intervention study, mice were 
treated with 1000 mg/liter phenylbutyrate dissolved in the drinking water.  Control 
animals received water with sodium chloride added to the same molarity as the sodium in 
the drug-treated animals.  
Rotarod test 
Mice were tested for their ability to run on a 3-cm diameter rotating rod (rotarod) 
at speeds ranging from 3 to 33 rpm. The protocol consisted of two phases: habituation 
(Day 1) and rotarod training/testing (Days 2–5). During habituation on Day 1, the mice 
were trained to remain on the rotarod at 3 rpm. During training/testing on Days 2–5, mice 
were placed on the rotating rod at a constant speed for three one-minute trials with a 5-
min rest interval between trials. Each test day, the speed was increased, reaching 33 rpm 
by Day 5. The time the mice spent on the rotarod without falling was recorded for each 
trial.  
Morris water maze testing 
Spatial learning was assessed using the Morris water maze. The maze included a 
circular tank (120 cm in diameter) filled to 10 cm below the edge of the tank with 27 °C 
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water that was made opaque by the addition of non-toxic black ink. A circular escape 
platform (10 cm in diameter) was located 1 cm below the surface of the water in a 
constant location in the northwest quadrant of the tank. Mice were first acclimated to the 
maze during three trial habituation sessions. Each testing session consisted of three 
consecutive days with four trials per day. The platform was invisible in the pool, and 
mice were allowed to swim for 60 seconds before being returned to the home cage. The 
latency from all training and testing sessions was collected.  
Analysis of brain for DJ-1 and α-synuclein 
The mouse brains were dissected and homogenized in dissociation buffer with 
protease inhibitors. Protein concentration was determined by the BCA method.  Fifty µg 
of protein was separated on 10% SDS-PAGE gel and transferred to a nitrocellulose 
membrane. Blot was probed with antibodies to DJ-1 (1:5000, Chemicon), α-synuclein 
(Syn-1 and LB509, 1:2000, Transduction Laboratories) and β-actin (1:4000, Sigma). 
Blots were incubated with HRP-conjugated secondary antibody (1:10,000; Jackson 
Immuno Research), followed by chemiluminescent detection.  Protein densities were 
quantified by ImageJ software after scanning into image file and normalized to β-actin.  
Statistics 
All experiments were repeated six times.  Significance was tested using 
multivariate ANOVA and the Tukey Honestly Significance Difference (HSD) post-hoc 
tests and Student’s paired T-tests.  Significance was set at p < 0.05.  Values are shown as 






HDACi Phenylbutyrate up-regulates DJ-1 in vitro 
There is increasing evidence that administration of histone deacetylase (HDAC) 
inhibitors can exert neuroprotective effects by a variety of mechanisms.   To perform 
gene expression, a cell must control the coiling and uncoiling of DNA around histones.  
This is accomplished with the assistance of histone acetylases (HAT), which acetylate 
lysine residues in core histones.  Acetyl groups force the DNA structure wound around 
the histone groups to loosen, allowing room for binding of transcription factors and RNA 
polymerase and ultimately leading to a more transcriptionally active chromatin.  
Conversely, the actions of HDACs, which remove the acetyl groups from histones, lead 
to a more compacted and transcriptionally silenced chromatin.  HDAC inhibitors 
(HDACi) block this action and cause hyperactylation of histones, thereby affecting gene 
expression in the surrounding region of the genome (Fig. 11). 
Sodium phenylbutyrate is an FDA-approved oral medication for 
hyperammonemia.  Sodium phenylbutyrate readily crossed the blood brain barrier and is 
known to readily β-oxidize to sodium phenylacetate, its bioactive metabolite for 
treatment of hyperammonemia (Kemp et al, 1998; Thibault et al, 1997).  The HDACi 
sodium butyrate has been reported to prevent neurodegenerative phenotype in mouse 
models of DRPLA (dentatorubral-pallidoluysian atrophy and in a mouse model of spinal 
and bulbar muscular atrophy (Ying et al, 2006; Minamiyama M et al, 2004).   The 
HDACi sodium phenylbutyrate stops the neurodegeneration phenotype of a mouse model 
of Huntington’s disease and reverses the phenotype of a mouse model of Alzheimer’s 




Figure 11:  HDAC inhibitors remodel chromatin structure to promote gene 
expression 
Within the nucleus, DNA is coiled tightly around histones in a complex called chromatin.  
Chromatin remodeling is a dynamic process which is essential for correct gene 
expression.  Histone Deacetylase inhibitors (HDACi) alter chromatin remodeling and 
allow for transcriptional accessibility for certain genes and promote specifically induced 
gene expression. Adapted from Lodish et al, 2008.   
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reported that  phenylbutyrate can prevent dopamine cell death and protect against the 
neurodegenerative effects of MPTP toxicity, which has been used to model Parkinson’s 
disease in mice (Gardian et al, 2004).   
Since HDAC inhibitors such as sodium butyrate and sodium phenylbutyrate have 
neruoprotective effects, we screened a number of small molecule HDACi compounds for 
increased DJ-1 expression using HEK293 DJ-1 promoter-luciferase reporter cells.  
Treatment with a concentration range of sodium phenylbutyrate for 48 hours significantly 
increased luciferase activity by 3-fold at 150μM concentration.  Also, N27 rat dopamine 
neurons treated with the same range of concentrations of sodium phenylbutyrate.  Results 
show that that 150μM phenylbutyrate treatment increased DJ-1 protein levels to 300% 
control as measured by Western blot (Fig 12). 
Figure 12: Phenylbutyrate increases DJ-1 expression in HEK293 and N27 cells 
(A), HEK293 reporter cells expressing human DJ-1 promoter-Luciferase were treated 
with varying doses of phenylbutyrate for 48 hours, followed by Luciferase assay.  
Duplicate treatments in 24-well plates were used, and experiments were repeated three 
times. (B), N27 cells were treated with varying doses of phenylbutyrate for 48 hours.  The 
cell lysates were analyzed with Western blot and probed with DJ-1 and β-actin primary 
antibodies.  Duplicate treatments in 6-well plates were used, and experiments were 
repeated three times.  A typical Western blot is shown.  (C), Quantitative data from 
Western blot images are shown (*, p <0.05; **, p <0.01 compared with control, n = 6).  
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We have previously reported that overexpression of the DJ-1 gene through 
adenovirus transduction can make N27 cells more resistant to oxidative stress and that 
phenylbutyrate treatment is sufficient to up-regulate DJ-1 expression and protein levels in 
N27 cells.  To determine whether phenylbutyrate could replicate the protection against 
oxidative stress seen from overexpressing DJ-1 with adenovirus, N27 cells were treated 
with 150μM phenylbutyrate for 48 hours, then the cells were subjected to varying 
concentrations of H2O2 for 24 hours.  Quantitative results showed that phenylbutyrate 
treatment significantly increased cell viability after exposure to hydrogen peroxide 
compared with controls (Fig. 13).  
 
 
Figure 13:  Phenylbutyrate protects dopamine neurons from oxidative stress toxicity 
N27 cells were incubated with 150μM phenylbutyrate for 48 hours, followed by 24 hours 
of treatment with H2O2 at various concentrations.  Cell viability was determined by MTT 
assays.  Triplicate treatments in 24-well plates were used, and experiments were repeated 




Additionally, we have shown that overexpression of the DJ-1 gene through 
adenovirus transduction can make N27 cells resistant to cell death from expression of 
A53T mutant human α-synuclein.  To determine whether phenylbutyrate could replicate 
the protection against mutant α-synuclein seen from DJ-1 overexpression with 
adenovirus, we treated N27 cells with 150μM phenylbutyrate for 48 hours and then 
exposed to adenovirus expressing A53T mutant α-synuclein for 48 hours. Treatment with 
phenylbutyrate increased cell viability and reduced the number of cells with α-synuclein 
aggregates compared with controls (Fig. 14).  Taken together, these data indicate that the 
drug phenylbutyrate can protect dopamine neurons from oxidative stress and mutant α-
synuclein toxicity in rat dopamine neuron cell culture. 
 
Figure 14: Phenylbutyrate protects dopamine neurons from mutant α-synuclein 
toxicity  
N27 cells were incubated with various doses of phenylbutyrate for 48 hours followed by 
48 hours of treatment of adenovirus expressing A53T human α-synuclein at 200pfu/cell.  
Cell viability was determined by MTT assays.  N27 cells containing aggregates were 
identified by α-synuclein antibody LB509 staining.  Triplicate treatments in 24-well 
plates were used; experiments were repeated three times (*, p <0.05; **, p <0.01 




In order to test whether DJ-1 protein is required for the protective effects of 
phenylbutyrate treatment on dopamine neurons, protein knockdown technology was used.  
To knock down endogenous DJ-1 protein in N27 cells, a short hairpin RNA (shRNA) to 
rat DJ-1 was designed.  A 75-bp synthesized DNA fragment encoding DJ-1 shRNA 
(called shDJ-1) was cloned into an adenovirus vector.  N27 cells were transduced with 
adenovirus expressing shDJ-1 at a concentration of 200pfu/cell for 48 hours. Up to 85% 
knock down of endogenous DJ-1 with shDJ-1 was verified with Western blot (Fig. 15A).   
The cells were then treated with or without 150μM phenylbutyrate for 48 hours followed 
by exposure to 75μM or 100μM H2O2 for 24 hours.  Results confirm that shDJ-1 
knockdown in N27 cells effectively eliminated the neuroprotective effect of 
phenylbutyrate against oxidative stress toxicity.  In contrast, N27 cells that express 
endogenous levels of DJ-1 (control) treated with phenylbutyrate significantly improved 
cell viability (Fig. 15B).  
Phenylbutyrate increases DJ-1 and stops progression of disease in a transgenic 
model of diffuse Lewy body disease 
Phenylbutyrate is sufficient to up-regulate the neuroprotective gene and protein 
DJ-1 in dopamine neuron cell culture and protect the cells from pathological hallmarks of 
Parkinson’s disease.  As a result, we investigated whether phenylbutyrate could prevent 
neurodegeneration and progression of disease in vivo. As described in Zhou et al, 2008, 
our lab has generated a transgenic mouse model over-expressing the human Y39C mutant 
α-synuclein gene controlled by brain neuron-specific mouse Thy1 promoter. These mice 
widely express human mutant α-synuclein throughout the brain and develop progressive 




Figure 15: Knockdown of endogenous DJ-1 abolishes neuroprotection against 
oxidative stress from hydrogen peroxide 
(A), A sample western blot showed more than 85% reduction of endogenous DJ-1 
remained when cells were treated with 200pfu/cell shDJ-1 adenovirus. (B), N27 cells 
were transduced with adenovirus expressing shDJ-1 or Ad-GFP (control) at 
concentrations of 200pfu/cell for 48 hours.  The cells were then treated with or without 
150μM phenylbutyrate for 48 hours followed by exposure to H2O2 for 24 hours.  Cell 
viability was measured by MTT assay.  Results showed that knockdown of DJ-1 
abolished neuroprotective effects of phenylbutyrate against oxidative stress in N27 cells.  
Triplicate treatments in 24-well plates were used, and experiments were repeated three 




phenylbutyrate treatment in Y39C α-synuclein transgenic (Tg) mice would increase DJ-1 
levels and prevent the age dependent development of behavioral and neuropathological 
deficits. 
 Since sodium phenylbutyrate is stable in solution and since it has a very short 
half-life in vivo—0.8 hours—the drug was administered to the mice in the drinking water. 
The Y39C α-synuclein Tg mice were divided into two groups of 12 mice each:  Young 
Tg—6-8-months old—and Old Tg—10-12-months old.  Six Young Tg mice and six Old 
Tg mice received sodium phenylbutyrate in the drinking water at a concentration of 1000 
mg/liter (5.4 mM) for 12 weeks.  The other six Young Tg mice and six Old Tg mice 
received vehicle, NaCl, in the drinking water at a concentration of 310 mg/liter (5.3 mM) 
for 12 weeks.  Mice were tested for motor function after 6 weeks and 12 weeks of 
treatment using a Rotarod with increasing speed (3-33 rpm).  Mice were tested for 
cognitive function at 6 weeks and 12 weeks of treatment using a Morris water maze.  
After 12 weeks, the mice were sacrificed by deep anesthesia followed by intracardiac 
perfusion with saline and 4% paraformaldehyde.  The mouse brains were isolated, 
separated into sections: cortex (Ctx), striatum (Str), and hippocampus (Hip).  The 
sections were homogenated and brain proteins isolated for Western blot assays to 
measure DJ-1 protein levels and α-synuclein monomer and oligomer levels.   
To determine whether treatment with phenylbutyrate can prevent the motor 
decline seen in the Y39C α-synuclein Tg mice, the motor function of Tg mice was tested 
throughout the treatment period.  As previously reported, Y39C α-synuclein Tg mice 
have progressive, age-related decline in motor function as measured by reduced ability to 
remain on a rotating rod (Rotarod) as the rate of rotation increases.  Transgenic mice with 
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and without phenylbutyrate in the drinking water were tested for motor function after 6 
and 12 weeks of treatment using a Rotarod with increasing speed—from 3 rpm to 33 rpm.  
These behavioral tests showed that phenylbutyrate treatment did not affect motor 
function in Young Tg mice at 6 and 12 weeks of treatment.  This result is to be expected 
since the progressive age-related motor deficits of the Y39C α-synuclein transgenic mice 
have not yet developed in the Young Tg mice.  However, as expected in Old Tg mice, 
motor function deteriorated progressively with age in mice without phenylbutyrate 
treatment. Importantly, phenylbutyrate treatment was sufficient to significantly reduce 
the expected motor decline characteristic of Old Tg mice (Fig. 16). Three months of 
phenylbutyrate treatment significantly protects the Old Y39C α-synuclein Tg mice from 
behavioral motor decline. 
To determine whether phenylbutyrate treatment can also protect against the 
development of cognitive deficit seen in the Y39C α-synuclein Tg mice, the cognitive 
function of mice was tested throughout the treatment period.  As previously reported, 
Y39C α-synuclein Tg mice have progressive, age-related decline in spatial learning as 
measured by their ability to remember the location of a hidden platform in a Morris water 
maze.  Transgenic mice with and without phenylbutyrate in the drinking water were 
tested for cognitive function after 6 and 12 weeks of treatment using the Morris water 
maze.  As expected, the behavioral tests showed Young Tg mice performed well in the 
Morris water maze and phenylbutyrate treatment did not impact cognitive function at this 
age.  On the other hand, in Old Tg mice, treatment with phenylbutyrate was sufficient to 
significantly reduce the expected age-related decline in Morris water maze function after 




Figure 16: Phenylbutyrate improves motor function in aged α-synuclein transgenic 
mice.  
The Y39C transgenic mice were divided into two age groups: 6–8 months old (Young 
Tg, n = 20) and 10–12 months old (Old Tg, n = 20).  Half of the transgenic mice in each 
age group (n = 10) received 1000 mg/liter phenylbutyrate in drinking water, while the 
other mice (n = 10) were treated with water containing sodium chloride in equal molarity 
(vehicle). At 6 weeks and 12 weeks of drug treatment, all mice were tested for motor 
function using a rotarod (speed 3–33 rpm). Young Tg mice had no differences in rotarod 
performance between phenylbutyrate and vehicle treatments.  Phenylbutyrate treatment in 
Old Tg mice led to significant improvement in rotarod performance compared with 
vehicle-treated transgenic mice at both 6 week and 12 week tests. (*, p < 0.05; **, p < 
0.01; n = 10).  
 
phenylbutyrate treatment can significantly protect the Old Y39C α-synuclein Tg mice 
from cognitive decline. 
The data show that phenylbutyrate treatment can protect transgenic mice against 
the progressive decline in motor and cognitive function; I hypothesized that the 
prevention of behavioral decline was due to up-regulation of the neuroprotective gene 






phenylbutyrate in the drinking water were measured and compared with mice given 
vehicle in the drinking water.   Tissue lysates of cortex ant striatum brain sections (Ctx 
and Str, respectively) were separated in an SDS-PAGE gel and probed with mouse- and 
human-specific DJ-1 primary antibody.  Figure 18 shows a representative Western blot 
image from Young and Old Tg mice (10mTg and 15mTg, respectively) with and without 
phenylbutyrate treatment.  These results demonstrate that brain DJ-1 protein levels were 
significantly increased in both Young and Old Tg mice treated with phenylbutyrate 
compared with age-matched control mice without phenylbutyrate treatment.  
Phenylbutyrate treatment significantly increases brain DJ-1 protein levels regardless of 
age.  
In addition to DJ-1 protein levels, total α-synuclein levels and α-synuclein 
oligomer formation in transgenic mice treated with phenylbutyrate were examined.  
Tissue lysates of cortex, striatum and hippocampus brain sections (Ctx, Str and Hip) were 
separated in an SDS-PAGE gel and probed with SYN1 α-synuclein primary antibody 
which detects both mouse and human orthologs of α-synuclein.  Figure 19 shows 
representative Western blot images from Young and Old Tg mice (10mTg and 15mTg, 
respectively) with and without phenylbutyrate treatment.  Brain sections from Young Tg 
mice with and without phenylbutyrate treatment have developed very few α-synuclein 
oligomers, regardless of phenylbutyrate treatment.  This is to be expected because the 
pathological oligomer formation in this mouse model is progressive and significant 
oligomer formation has not yet developed at 10 months of age.  On the other hand, all of 
the brain sections from an Old Tg mouse not treated with phenylbutyrate show 
substantial α-synuclein oligomer accumulation as well as an increase in α-synuclein 
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monomer levels.  Importantly, phenylbutyrate treatment dramatically reduced α-
synuclein oligomers and slightly reduced α-synuclein monomer levels in Old Tg mice.  
The ratio of toxic α-synuclein oligomer to monomer is dramatically reduced by treatment 
with phenylbutyrate (Fig. 19). 
 
 
Figure 17: Phenylbutyrate improves cognitive function in aged α-synuclein 
transgenic mice  
The Y39C transgenic mice were divided into two age groups: 6–8 months old (Young 
Tg, n = 20) and 10–12 months old (Old Tg, n = 20). Half of the transgenic mice in each 
age group (n = 10) received 1000 mg/liter of phenylbutyrate in drinking water, while the 
other mice (n = 10) were treated with water containing sodium chloride in equal molarity 
(vehicle). After 6 weeks and 12 weeks of drug treatment, all mice were tested for 
cognitive function using the Morris water maze.  Young Tg mice had no differences in 
learning ability between phenylbutyrate and vehicle treatments. Phenylbutyrate treatment 
in Old Tg mice significantly improved learning ability in the last day of water maze 
testing compared with vehicle-treated transgenic mice at both 6-week and 12-week tests. 






Figure 18: Phenylbutyrate increases brain DJ-1 levels in young and old α-synuclein 
transgenic mice 
The Y39C transgenic mice were divided into two age groups: 6–8 months old (Young 
Tg, n = 20) and 10–12 months old (Old Tg, n = 20). Half of the transgenic mice in each 
age group (n = 10) received 1000 mg/liter phenylbutyrate in drinking water, while the 
other mice (n = 10) were given water with equimolar of sodium chloride (vehicle).  After 
12 weeks of treatment, the mice were sacrificed for biochemical analysis.  Brain tissues 
(cortex) from Young and Old transgenic mice with or without phenylbutyrate treatment 
were analyzed for DJ-1 protein levels using Western blot. Results showed that 
phenylbutyrate treatment significantly increased brain DJ-1 levels in both young and old 









Figure 19: Phenylbutyrate reduced α-synuclein oligomer formation and aggregation 
in aged transgenic mice 
The Y39C transgenic mice were divided into two age groups: 6–8 months old (Young 
Tg, n = 20) and 10–12 months old (Old Tg, n = 20). Half of the transgenic mice in each 
age group (n = 10) received 1000 mg/liter phenylbutyrate in drinking water, while the 
other mice (n = 10) were given water with equimolar of sodium chloride (vehicle). After 
12 weeks of drug treatment the mice were sacrificed for biochemical analysis.  Brain 
tissues (cortex, striatum, and hippocampus) from Young and Old transgenic mice with or 
without phenylbutyrate treatment were analyzed for α-synuclein aggregation. Western 
blots showed that phenylbutyrate dramatically reduced α-synuclein oligomer formation in 
old transgenic mice compared with mice of the same age not receiving phenylbutyrate 
treatment. A sample blot shows 15 month Tg with (+PB) or without (−PB) treatment), 
while α-synuclein monomer levels were not changed.  The graph shows the ratio of α-
synuclein oligomer to monomer is shown in Young and Old transgenic mice with or 
without phenylbutyrate treatment.  Old transgenic mice had high levels of oligomer 
(15%). After three months of phenylbutyrate treatment, old mice had much lower levels 
of oligomer which were similar to the ratio seen in Young transgenic mice (**, p < 0.01; 







Overexpression of DJ-1 in rat dopamine neuron cell culture is neuroprotective 
against both pathological hallmarks of Parkinson’s disease—oxidative stress and 
abnormal α-synuclein aggregation—by activation of distinct protective pathways.  
Therefore, DJ-1 up-regulation may be a good target for therapies aimed at stopping the 
dopamine cell death and progression of Parkinson’s disease.  HDACis have been 
proposed to have neuroprotective effects and have been proposed for treating a number of 
neurodegenerative disorders.  A number of HDACis were screened using a DJ-1 
promoter-Luciferase reporter cell line.  Results indicated that the HDACi phenylbutyrate 
can up-regulate DJ-1 four-fold in DJ-1- Luciferase reporter cells and three-fold in rat 
dopamine neurons (N27 cells).  Also, phenylbutyrate can rescue dopamine neurons from 
toxicity caused by oxidative stress as well as toxicity caused by abnormal α-synuclein 
aggregation.  Importantly, the neuroprotective effects of phenylbutyrate against these 
toxins were abolished with the knockdown of endogenous DJ-1 levels in the cells.  These 
findings confirm that phenylbutyrate is sufficient to up-regulate DJ-1 in dopamine 
neurons to level that the cells are protected from pathological toxins of Parkinson’s 
disease.   
Additionally, the data indicate that phenylbutyrate treatment in transgenic mice 
that overexpress a mutant form of α-synuclein will prevent phenotype development.  In 
mice, phenylbutyrate given in the drinking water can increase brain DJ-1 levels.  Up-
regulation of DJ-1 prevented toxic α-synuclein oligomer formation in brains of transgenic 
animals and prevented the age-related decline in motor and cognitive function.  
Therefore, phenylbutyrate may be a useful drug for preventing progression of disease in 
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patients with idiopathic Parkinson or diffuse Lewy body disease. Therapies that can 
increase DJ-1 expression could provide a new strategy for treating Parkinson disease by 





PHENYLBUTYRATE INCREASES CLEARANCE  




The α-synuclein gene (SNCA) is a highly conserved gene that is only expressed in 
the neocortex, hippocampus, substantia nigra, thalamus and cerebellum regions of the 
brain.  It is predominantly a neuronal protein, but can also be found in neuroglial cells.  
The exact function of α-synuclein protein has yet to be fully understood, but it is known 
to populate presynaptic terminals of the brain and may be involved in proper synaptic 
vesicle trafficking.  Although α-synuclein is exclusively expressed in brain neurons, 
recent studies indicate evidence of clearance of α-synuclein from the brain to the 
cerebrospinal fluid (CSF) and to the circulating blood plasma in humans.  In 2008, 
researchers detected several α-synuclein peptides by mass spectrometry in CSF from a 
neurologically healthy control.  They then compared CSF α-synuclein levels of de novo 
Parkinson’s patients and of healthy controls using an ELISA assay.  They found that 
mean CSF α-synuclein levels were lower in de novo Parkinson’s patients compared to 
healthy controls (Mollenhaur et al, 2008).  Around this time a separate group of 
researchers examined α-synuclein content in blood plasma of Parkinson’s patients and 
healthy controls using Western blot analysis.  They report that plasma α-synuclein levels 
in Parkinson’s patients were significantly lower than in age matched controls (Li et al, 
2006).   Together, these findings suggest that in healthy individuals there is a normal 
mechanism of clearance of α-synuclein from the brain to the CSF and plasma.  
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Additionally, the studies show a significant reduction in the amount of α-synuclein that is 
cleared to the CSF and plasma in Parkinson’s patients.  Persons with Parkinson’s disease 
may have a reduced ability of α-synuclein clearance from the brain to the CSF and 
plasma resulting in an abnormal build-up of intercellular α-synuclein leading to increased 
protein aggregation and toxic Lewy body formation. 
Research design and methods 
Phenylbutyrate treatment in α-synuclein transgenic mice 
All animal procedures were approved by Institiutional Animal Care and Use 
Committee (IACUC) at the University of Colorado Denver.  Our Y39C human α-
synuclein transgenic mouse model has been described (Zhou et al, 2008).  Human Y39C 
α-synuclein cDNA was cloned into the mouse pThy-1 vector at the NotI site.  The 
construct was micro injected into mouse oocytes and founder mice were identified by 
PCR and Southern blotting analysis.  Mice were bred to establish stable transgenic lines. 
Expression of human Y39C α-synuclein in these transgenic mice was determined by 
immunostaining and Western blotting with antibodies specific to human α-synuclein.   
Adult Y39C transgenic mice (4–6 months old) were treated with 1000 mg/liter 
phenylbutyrate dissolved in drinking water for 12 weeks. Mice typically drink 4–5 ml of 
water per day, and their drinking volumes were not affected by the addition of 
phenylbutyrate. Control animals received water with sodium chloride added to the same 
molarity as the sodium in the drug-treated animals.  
Western blotting 
The mouse plasma was collected after 12 weeks of drug treatment. Protein 
concentrations were determined by the BCA method.  Fifty µg of protein was separated 
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on 10% SDS-PAGE gel and transferred to a nitrocellulose membrane. Blot was probed 
with antibodies to α-synuclein (Syn-1 and LB509, 1:2000, Transduction Laboratories). 
Blots were incubated with HRP-conjugated secondary antibody (1:10,000; Jackson 
Immuno Research), followed by chemiluminescent detection.  Protein densities were 
quantified by ImageJ software after scanning into image file. 
Phase I human clinical safety trial of phenylbutyrate 
 Twelve Parkinson’s disease patients with newly diagnosed idiopathic Parkinson’s 
disease were recruited for a Phase I clinical safety trial of phenylbutyrate.  All patients 
were Hoehn and Yahr stage 1 or 2 in the “off” state.  The average age of the patients was 
62 +/- 6 years; there were 6 men and 6 women included in the study.  Phenylbutyrate is 
FDA-approved for a dose up to 20 grams per day.  For this study, doses started at 
1gm/day and progressed to 16g/day after 6 months.  Plasma and serum samples were 
collected throughout the study for biochemical analysis.   
MALDI-TOF mass spectrometry  
 Plasma phenylbutyrate and phenylacetate levels were quantified using Matrix 
Assisted Laser Desorption/Ionization-Time of Flight (MALDI-TOF) Mass Spectrometry 
analysis.  Organic compounds were extracted from human plasma samples with 
acetonitrile.  Extracted samples were spiked with 1 μg of phenyl propionic acid which 
was used as an internal standard.   The spiked samples were then incubated derivitizing 






Patient plasma analysis with ELISA and Western blotting 
Patient blood was collected though transcadiac needle with syringe containing 
EDTA as anti-coagulate throughout the trial. The blood was centrifuged at 2000 rpm for 
5 min.  After centrifugation, the plasma fraction was collected and stored at -80C.  The 
small portion of plasma was used to determine DJ-1 concentration using ELISA kit 
(CircuLex), according to manufacturer’s instructions.  Additionally, total levels of α-
synuclein were determined with a human α-synuclein ELISA kit (Invitrogen).  Also, 
human plasma was analyzed for α-synuclein levels by Western blot analysis.  Blots were 
probed with antibodies to α-synuclein (LB509, 1:2000, Transduction Laboratories) and 
albumin (1:2000, Sigma). Blots were incubated with HRP-conjugated secondary antibody 
(1:10,000; Jackson Immuno Research), followed by chemiluminescent detection.  Protein 
densities were quantified by ImageJ software after scanning into image file and 
normalized to albumin levels. 
Statistics 
 Signifcance was tested using multivariate ANOVA and the Tukey Honestly 
Significance Difference (HDS) post-hoc tests and Studen’ts paired T-tests.  Significance 
was set at p < 0.05.  Values are shown as mean ± SEM. 
 
Results 
Phenylbutyrate enhances α-synuclein clearance in α-synuclein transgenic mice 
The Y36C α-synuclein transgenic mouse model over-expresses the human mutant 
α-synuclein gene which is controlled by the brain neuron-specific mouse Thy1 promoter.  
These mice widely express human mutant protein throughout the brain as determined by 
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immunohistochemical staining with the human-specific LB509 α-synuclein antibody and 
the mouse- and human-specific SYN1 α-synuclein antibody.  In this animal, we found 
that brain α-synuclein is 50% human and 50% mouse (Zhou et al, 2008).  As previously 
reported, phenylbutyrate treatment increased DJ-1 expression and reduced α-synuclein 
oligomer formation and aggregation in aged transgenic mice.  The Y39C α-synuclein 
transgenic mice were divided into two age groups:  6-8 months old (Young Tg) and 10-
12 months old (Old Tg).  Half of the transgenic mice in each age group received 
phenylbutyrate in drinking water, while the other mice were given water with equimolar 
sodium chloride (vehicle).  After 12 weeks of drug treatment the mice were sacrificed for 
biochemical analysis.   Cortex, striatum and hippocampus brain tissues from Young and 
Old Tg mice with or without phenylbutyrate treatment were analyzed for α-synuclein 
aggregation.  Western blots showed that phenylbutyrate dramatically reduced α-synuclein 
oligomer formation in old transgenic mice compared with mice of the same age receiving 
vehicle, while monomer levels were not changed (Fig. 19).  These results indicate that 
phenylbutyrate treatment is sufficient to reduce human α-synuclein oligomers in the brain 
of Y39C α-synuclein transgenic mice.   
Since phenylbutyrate treatment significantly reduced the amount of α-synuclein 
oligomers in brain sections of Y39C α-synuclein transgenic mice, I hypothesized that 
there is a mechanism of clearance of α-synuclein from the brain to the circulating plasma 
and that this mechanism may be enhanced by phenylbutyrate.  To test this hypothesis, 
plasma samples were analyzed from transgenic mice given no drug (Tg), Tg mice treated 
with 1000mg/L phenylbutyrate in drinking water for one week (Tg+PB), and non-Tg 
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mice (nTg).  Plasma α-synuclein levels were detected by Western blot analysis using     
α-synuclein antibodies. The top blot was exposed to the human-specific LB509  
α-synuclein primary antibody and shows human α-synuclein is present in brain and 
plasma of only transgenic mice.  In addition, there is no human α-synuclein present in the 
muscle of the mice confirming that the brain-neuron specific mouse Thy1 promoter is 
only expressing human α-synuclein in the brain.  All human α-synuclein detected in the 
plasma, then, must have been mobilized from the brain.  The lower Western blot contains 
the same samples, but was exposed to the Syn-1 antibody that detects both human and 
mouse α-synuclein.  This blot will detect the human α-synuclein that came from the brain 
as well as the endogenous mouse α-synuclein.  Corresponding to our observation of 
human to mouse α-synuclein ratio in brains of transgenic mice, plasma α-synuclein level 
is also 50:50 human to mouse; this observation indicates that plasma α-synuclein has 
come primarily from brain neurons.  This figure also suggests that treatment with 
phenylbutyrate for one week significantly increases both the total monomer and oligomer 
α-synuclein levels in the plasma (Fig.20).  We conclude that treatment with 
phenylbutyrate induces clearance mechanisms of α-synuclein from the brain to the 
plasma of Tg mice.  
Phenylbutyrate enhances α-synuclein clearance in Parkinson’s patients 
Experiments show that the drug phenylbutyrate incudes clearance of α-synuclein 
oligomers and monomers from the brain to the plasma in Y39C α-synuclein transgenic 
mice.  Next, experiments were done to determine whether phenylbutyrate treatment was 
able to increase α-synuclein clearance in persons with Parkinson’s disease as measured 
by elevated plasma α-synuclein levels.  We organized a human Phase I clinical safety  
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Figure 20: Phenylbutyrate increases α-synuclein monomers and oligomers in the 
plasma of transgenic mice 
Y39C transgenic mice aged 10- to 12-months were divided into two groups:  transgenic 
mice given 1000mg/L phenylbutyrate in the drinking water for one week (Tg + PB; n = 
6) and transgenic mice given water with equimolar sodium chloride (vehicle) for one 
week (Tg; n=6).   Additionally, a group of WT littermates were given water with sodium 
chloride (vehicle) for one week (nTg; n=6).  After one week of drug treatment, blood 
plasma samples from all mice were obtained and analyzed for human and mouse α-
synuclein content.  Also, transgenic mice treated with vehicle were sacrificed and whole 
brain and skeletal muscle samples were obtained for analysis of α-synuclein content.  The 
top representative Western blot image was probed with LB509 α-synuclein primary 
antibody that is specific for the human ortholog of α-synuclein.  The bottom 
representative Western blot image was probed with Syn-1 α-synuclein primary antibody 
that detects both human and mouse orthologs.  The results indicate that human α-
synuclein monomers and oligomers are present in plasma and brain of Y39C transgenic 
mice, but are not detected in the muscle.  Also, phenylbutyrate treatment for one week 
increases clearance of human α-synuclein monomers and oligomers.  Transgenic mice 
have 50:50 ratio of human to mouse α-synuclein in the plasma and, as expected, non-
transgenic WT littermates have not human α-synuclein in the plasma.  Graphs of human 
α-synuclein oligomers and monomer and total human α-synuclein in plasma for 
transgenic mice with and without phenylbutyrate treatment are shown.  Phenylbutyrate 
increase plasma α-synuclein oligomers and monomers after one week of treatment; total 




trial of phenylbutyrate in 12 Parkinson’s patients with newly diagnosed idiopathic form 
of Parkinson’s disease, Hoehn and Yahr stage 1 or 2 in the “off” state; the average age of 
patients was 62 +/- 6 years. In a dose-ranging study, 12 Parkinson’s patients doubled 
their doses of phenylbutyrate on a monthly basis after pre-treatment monitoring period.  
Doses started at 1gm/day and progressed to 16gm/day after 6 months (Fig. 21).  Plasma 
was obtained every two weeks throughout the study for monitoring levels of 









Figure 21:  Phenylbutyrate dosing schedule for human Phase I clinical safety trial 
Twelve newly diagnosed Parkinson’s patients were recruited for a six-month Phase I 
clinical safety trial for phenylbutyrate.  Patients came to the clinic every two weeks for 
clinical assessment and blood sample obtainment.   After a one month pre-treatment 
monitoring period, patients started at one gram per day of drug and doubled their daily 
dose each month finishing at 16 grams of phenylbutyrate per day during the sixth month.  
The known metabolites of phenylbutyrate are phenylacetate and 
phenylacetylglutamine.  Phenylbutyrate has a half-life of 0.8 hours in humans and is 
known to rapidly metabolize to phenylacetate; phenylacetate then conjugates with 
glutamine via acytlation to form phenylacetylglutamine.  These metabolites are excreted 
in the urine.  Plasma phenylbutyrate and phenylacetate levels were measured using 
MALDI-TOF-Mass Spectrometry analysis.  Organic compounds, including 
phenylbutyrate and its metabolites were extracted from human plasma samples.  Plasma 
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Phase I clinical 
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extracts were spiked with equal amounts of phenyl propionate which was used as an 
internal control.  Samples were analyzed using MALDI-TOF Mass Spectrometry for 
phenylbutyrate and phenylacetate quantitation.   As expected, there was a dose-dependent 
correlation in the levels of phenylbutyrate and phenylacetate in plasma (Fig. 22).  The 
plasma drug levels were useful in determining if patients were consuming the dosage of 
drug they were supposed to.  Patient blood samples that did not contain the expected 
levels of phenylbutyrate and phenylacetate that corresponded to the dose of drug they 
claimed to be taking were eliminated from further testing.  
 
 
Figure 22:  Phenylbutyrate and phenylacetate levels in patient plasma correspond to 
daily dose of drug 
Patient blood samples were drawn one hour after the first daily dose of phenylbutyrate in 
the morning.  Plasma phenylbutyrate and its metabolite phenylacetate were detected 
using MALDI-TOF Mass Spectometry.  These measurements were useful in monitoring 
whether patients were consuming the appropriate dose of phenylbutyrate.  Plasma levels 



























































































Phenylbutyrate in Patient Plasma: 

























































































Phenylacetate in Patient Plasma: 
Plasma drawn 1 hour after last dose 
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Brain DJ-1 levels cannot be directly measured in human subjects, so we need to 
rely on an increase in plasma DJ-1 to indicate a possible dose-related increase of DJ-1 in 
the brain.  Other studies reported that the majority (99%) of DJ-1 in whole blood resides 
in erythrocytes and less than 1% is detected in the plasma (Xu et al, 2010).  Therefore the 
effects of lysed red blood cell contamination in the plasma must be accounted for.  Red 
blood cell lysis contamination in patient plasma samples was measured using a human 
hemoglobin ELISA.  Plasma samples with hemoglobin concentrations of 20μg/μl or 
higher were considered contaminated with red blood cell lysates and the samples were 
not used for analysis (Kruszyna et al, 1977).  The vast majority (115 out of a total of 119 
plasma samples) had very little hemoglobin concentration (less than 0.5ug/ul) and these 
samples were used for measurements of plasma DJ-1 levels. 
Phenylbutyrate dose-related DJ-1 concentration increase was expected from data 
obtained from Y39C transgenic mice treated with phenylbutyrate in the drinking water 
(Fig. 18).  Plasma DJ-1 concentration from Parkinson’s disease patients taking increasing 
doses of phenylbutyrate were measured using a human DJ-1 ELISA assay.  The expected 
correlation between phenylbutyrate dose and plasma DJ-1 concentration was not seen 
(Fig. 23).  In fact, there was high variability in plasma DJ-1 concentration from patient-
to-patient and from week-to-week, not dependent on phenylbutyrate dose.  
Although the patients were consuming the appropriate dosages of phenylbutyrate 
as detected by Mass Spectrometry analysis of the blood samples (Fig. 22), the expected 
corresponding increase in plasma DJ-1 protein concentration was not seen.  However, I 
did notice an interesting phenomenon concerning DJ-1 expression.  When normalized 




Figure 23:  Parkinson’s patients’ DJ-1 concentration in plasma did not increase with 
phenylbutyrate treatment 
Plasma samples from Parkinson’s patients involved in the phase I clinical safety trial of 
phenylbutyrate were collected and DJ-1 concentration was determined using ELISA.  
Although a dose-dependent increase in plasma DJ-1 concentration was expected, this 
phenomenon was not observed.  Instead, DJ-1 concentrations in patient plasma did not 
correlate to phenylbutyrate dose and was found to be highly variable from patient to 
patient as well as from week to week.   (Error bars represent SEM; n = 8). 
 
there was a statistically significant peak in average DJ-1 levels from mid-December to 
the beginning of January (Fig. 24). This unexpected result expanded my perspective on 
the factors contributing to DJ-1 levels in human plasma.  There are a number of 
environmental factors that can change during the winter holiday season that could 
contribute to this “holiday phenomenon.”  
Among possible environmental factors, activity level, stress level and diet are 
among the feasible variables that change during the holiday season.  Since the baseline 
mice used in the original in vivo phenylbutyrate study were highly sedentary in their 
cages, I designed mouse experiments to investigate the hypothesis of increased activity 
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Figure 24: Patient plasma DJ-1 levels are significantly higher from mid-December 
to early-January 
Previous experiments in mouse models led to the hypothesis that the DJ-1 levels in 
patients would increase corresponding to the dose of phenylbutyrate.  However, there was 
no dose dependent increase in DJ-1.  Interestingly, when the normalized average DJ-1 
levels of all 12 pateints in the trial were plotted as a function of date regardless of dose of 
phenylbutyrate, we observed an interesting phenomenon.  The average normalized DJ-1 
level for all patients were significantly higher during the blood draws during the weeks 
between mid-December and early-January.  Each data plot represents the average DJ-1 
levels normalized to individual baseline values (n = 12; *, p < 0.05; Image created by 
Alberto Costa).  
 
The theoretical basis for these experiments, the methods used and the results from the 
exercise experiments are explained in detail in Chapter V. 
In addition to DJ-1 levels, we also examined the plasma samples from the Phase I 
human clinical safety trial for dose-dependent increase in α-synuclein levels.   A dose-
dependent increase in plasma α-synuclein would indicate that phenylbutyrate induces 





















































clearance of toxic α-synuclein from the brains to the plasma of Parkinson’s patients.  I 
measured plasma α-synuclein levels by Western blot analysis using the SYN1 primary 
antibody against α-synuclein and the Albumin primary antibody as a loading control for 
the assay.  To validate the Western blot results, I also measured total plasma α-synuclein 
using the ELISA kit that detects human α-synuclein.  The results of these assays indicate 
that there is a significant increase in plasma α-synuclein levels on average between 
baseline 0 grams per day and a dose of 16 grams per day phenylbutyrate (Fig 25). These 
results led to the conclusion that there is a mechanism of clearance of α-synuclein from 
the brain to the circulating plasma in patients with Parkinson’s disease and that this 
clearance is enhanced by phenylbutyrate treatment.    
Figure 25:  Phenylbutyrate treatment increases plasma α-synuclein in Parkinson’s 
patients. 
Newly diagnosed Parkinson’s patients participated in a 6-month Phase I clinical safety 
trial of phenylbutyrate.  Every two weeks throughout the study, blood samples were 
collected for analysis of plasma levels of α-synuclein.  Protein levels were analyzed using 
Western blot analysis using Syn-1α-synuclein primary antibody and normalized with 
Albumin primary antibody as a loading control.  Additionally, a human α-synuclein 
ELISA kit was used to verify plasma α-synuclein levels; these values were normalized to 
each individual’s baseline plasma α-synuclein concentration.  Results indicate that at a 
dose of 16 grams per day, phenylbutyrate treatment significantly increases plasma α-
synuclein levels compared to individual patient baseline plasma α-synuclein levels (*, p < 





























































































































Phenylbutyrate enhances α-synuclein clearance in rat dopamine neurons 
We have shown that there is significant increase of α-synuclein clearance from 
the brain to the blood when Y39C α-synuclein transgenic mice were administered 
1000mg/L of phenylbutyrate in the drinking water for 1 week and when Parkinson’s 
patients enrolled in our Human Phase I clinical safety trial were treated with a dose of 16 
grams of phenylbutyrate a day.  My hypothesis is that the increased level of plasma        
α-synuclein is due to the mobilization of toxic α-synuclein from the midbrain dopamine 
neurons.  To test this hypothesis, I performed an in vitro study in the N27 rat 
dopaminergic cell line looking at α-synuclein content before and after treatment with 
phenylbutyrate.  N27 cells were treated with naïve cell culture media or with cell culture 
media enriched with 150μM phenylbutyrate for 24 hours.  After 24 hours, the media from 
the untreated cell culture and from the phenylbutyrate-treated cell culture was collected 
and concentrated to one tenth the volume; additionally, proteins were extracted from 
untreated and from phenylbutyrate-treated cell lysates.  The level of α-synuclein in cell 
lysates and in cell media supernatant were detected with Western blot using the SYN1   
α-synuclein primary antibody.  The results indicate that when N27 dopamine neurons are 
treated with phenylbutyrate for 24 hours in cell culture, there is a significant reduction in 
intercellular levels of α-synuclein and a significant increase in the amount of α-synuclein 
in the cell media supernatant (Fig. 26).   
The N27 cell culture results confirm that there is endogenous α-synuclein present 
within dopamine neurons and present in the cell culture supernatant in the untreated cell 
cultures.  Additionally, treatment with phenylbutyrate reduces the intercellular levels of 
α-synuclein and increases the amount that is cleared from the dopamine neurons to the 
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surrounding media.  This finding supports the in vivo findings from Y39C transgenic 
mouse studies and human Phase I clinical trial studies that there is a normal mechanism 
of clearance of α-synuclein from brain neurons to the circulating plasma, and that this 
clearance mechanism is enhanced with phenylbutyrate treatment.   
 
 
Figure 26: Treatment with phenylbutyrate induces mobilization of α-synuclein in 
vitro from within dopamine neurons to cell culture media. 
N27 cells were incubated with 150 μM phenylbutyrate or naïve culture media for 24 
hours.  After this time, the cell culture supernatant was collected and concentrated.  The 
proteins from the concentrated supernatant as well as from cell lysates were isolated.  The 
α-synuclein protein levels from supernatant and cell lysates were analyzed using Western 
blot with SYN1 primary antibody.  Cells treated with phenylbutyrate for 24 hours had 
significantly reduced intercellular α-synuclein and significantly greater α-synuclein 
mobilized to the supernatant compared to untreated cells.  Six well plates were used; 
experiments were repeated 3 times (*, p < 0.05; n = 6).   
 
To verify that the reduction of intercellular α-synuclein level and the increase in 
secreted α-synuclein level by phenylbutyrate is, in fact, a result of enhanced protein 
clearance rather than a drug toxicity effect, I performed an in vitro cell viability assay.  I 





















































concentrations of 0μM – 1000μM, including the 150μM used in the secretion in vitro 
assay described in Figure 26.  These data show that phenylbutyrate is non-toxic to 
dopamine neurons at 150μM; at this concentration there is 100% cell viability.  
Phenylbutyrate is only significantly toxic to dopamine neurons at a concentration of 
1000μM (Fig. 27).  These results indicate that the α-synuclein clearance from the 
intercellular space to the cell culture media seen in Figure 26 was actually a mechanism 
of clearance rather an artifact of cell membrane permeability caused by cellular toxicity 
and death. 
 
Figure 27:  Cell viability with phenylbutyrate treatment in vitro  
N27 cells were incubated with various doses of phenylbutyrate for 48 hours (0 μM – 
1000 μM).  Cell viability was determined by MTT assay and normalized to untreated 
cells.  Phenylbutyrate was only toxic to cells at concentrations above 1000 μM; at 150 
μM—the concentration used in in vitro clearance experiments—phenylbutyrate treatment 
had no toxicity.  Triplicate treatments in 24 well plates were used, the experiments were 







These findings led us to conclude that phenylbutyrate is non-toxic and enhances 
the endogenous mechanism of clearance of α-synuclein from dopamine neurons.  We 
have observed this effect in our Y39C α-synuclein transgenic mouse model of 
Parkinson’s disease administered phenylbutyrate in the drinking water.  We have also 
seen a significant increase in plasma α-synuclein levels in Parkinson’s patients enrolled 
in a Human Phase I clinical safety trial at a dose of 16 grams of phenylbutyrate a day.  
Finally, we have verified that the phenylbutyrate induced clearance mechanism of          
α-synuclein seen in mice and humans is endogenous to dopamine neurons and that this 
mechanism is enhanced by non-toxic phenylbutyrate treatment in vitro.  Taken together, 
these findings have provided insights into possible mechanisms of neuroprotection of 
phenylbutyrate treatment in our Y39C transgenic mouse model.  We now have an 
understanding that enhancing the clearance of toxic α-synuclein from brain neurons is a 






GENE REGULATION SCREEN REVEALS NEUROPROTECTIVE 
MECHANISMS ACTIVATED BY PHENYLBUTYRATE 
 
Introduction 
Phenylbutyrate up-regulates neuroprotective gene and protein DJ-1 and protects 
dopamine neurons in culture from both pathologic cellular stresses that lead to 
Parkinson’s disease: increased oxidative stress and abnormal protein aggregation.  
Furthermore, phenylbutyrate up-regulates brain DJ-1 in Y39C α-synuclein transgenic 
mice, prevents motor and cognitive decline and reduces brain α-synuclein oligomers.  
Also, phenylbutyrate is non-toxic to dopamine neurons and is sufficient to facilitate       
α-synuclein clearance in vitro, in a transgenic mouse model of diffuse Lewy body disease 
and in humans with Parkinson’s disease. Although we have conclusively shown that 
phenylbutyrate treatment prevents neurodegeneration through an up-regulation of DJ-1 
and enhances the clearance of α-synuclein from dopamine neurons, the genetic 
mechanism of neuroprotection of phenylbutyrate and the mechanism of clearance of toxic 
α-synuclein is yet to be fully understood.   
To reveal the detailed mechanisms of neuroprotection, I used a reverse-
transcription quantitative polymerase chain reaction (RT-qPCR) assay to study the 
activation of metabolic pathway expression in dopamine neurons after treatment with 
phenylbutyrate, exposure to hydrogen peroxide and overexpression of mutant α-
synuclein.  I examined the differential expression patterns of 30 genes known to be rate-
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limiting enzymes and important regulator genes in essential cellular survival pathways as 
well as the β-actin gene as an internal control (Table 2).  I analyzed essential genes in 
oxidative stress regulation pathways, protein catabolism pathways (including the 
ubiquitin-proteasome pathway and the lysosome/exosome vesicle trafficking pathway), 
mitochondrial regulation pathways, apoptosis pathways and nerve growth pathways.  The 
results from the in vitro qPCR screen indicate that out of the 30 genes screened, 
phenylbutyrate treatment significantly changes the expression pattern of 11 genes.   
Results show that phenylbutyrate treatment specifically enhances activation of the 
oxidative stress response genes DJ-1, NRF2, PRDX2 and GCL when cells are stressed 
with reactive oxygen species.  Conversely, phenylbutyrate specifically enhances 
activation of lysosome/exosome vesicle trafficking genes GBA, LAMP2 and VAMP2 and 
the ubiquitin-proteasome pathway gene SIAH1 and chaperone genes HSC70, HSP70 and 
HSP40 when cells are stressed with toxic α-synuclein oligomers.   
 






















 PARK7 Rv CCTCCACAATGGCCAGCGCA 
 
60 








  NRF2 Rv CCAAACTTGCTCCATGTCCT 
 
60 





 PRDX2 Rv AGGACTTCCGAAAGCTAGGC 
 
60 














 GCL Rv TGGCACCCACTCCTGGGCTT 
 
60 







 NOS1 Rv CGTGGGGGTCCCATTGGTGC 
 
58 







 eNOS3 Rv GGCATACCAGCGCAGGCCAA 
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System  FBX07 Rv TGGGATGTTAGCCTGGCTTG 
 
63 








 SIAH Rv ATGTAAGTTTGGGGCGACAG 
 
60 








 UCHL1 Rv GGGCCGTGAGGGGAAACAGC 
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 PLK2 Rv TGAGGACTTCAGGGGAGAGA 
 
60 






 PARK2 Rv CAGCCACACACGGCAGGGAG 
 
60 








 Hsc70 Rv CCAGCTCCTCCCGCTTGTGC 
 
60 






 Hsp4A Rv TGCTCAGCAGCTTGGGTGCC 
 
60 






 iHsp70 Rv AGTGCCACCTCCCAGGCAA 
 
60 











 VAMP2 Rv CTTGGCTGCACTTGTTTCAA 
 
60 






























 LAMP2 Rv GGCTGACAGCTGCCGGTGAA 
 
60 
XX FLOT1 Fw Flotillin 1 AGGCCCAGAGGGACTATGAG 
 
61 
 FLOT1 Rv CTCGATCTGCTGCTTCGTGT 
 
61 






 GBA Rv GGATTCAGGGCAAGGTTCCA 
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 ATG6 Rv GCTGCACACAGTCCAGAAAA 
 
64 






 ATG7 Rv GACGTGTCTGACGCCCCAGC 
 
60 






 ATG8 Rv GCGGCGCCGGATGATCTTGA 
 
60 















 PGC1α Rv TGCCCCTGCCAGTCACAGA 
 
60 







 PINK1 Rv ATCTGCTCCCTTTGAGACGA 
 
60 






 HTRA2 Rv TGGCAACAACAAACTCCCT 
 
63 








 CREB1 Rv ACGCCATAACAACTCCAGG 
 
62 




























 PTEN Rv TACACCAGTCCGTCCTTTCC 
 
60 












Study design and methods 
Culture of N27 cells and treatment with HDAC inhibitors 
 
Dopaminergic cells derived from embryonic day 12 rat mesencephalon and 
immortalized with the SV40 large T antigen designated 1RB3AN27 (N27 cells) were 
used (Adams FS, et al. 2006). N27 cells were cultured in 6-well plates in RPMI 1640 
medium containing 10% fetal bovine serum.  Cells were treated with sodium 
phenylbutyrate (PB, from Scandinavian Formulas) at a concentration of 100μM for 48 
hours, followed by exposure to a cellular toxin for 24 hours.  Cells were either exposed to 
oxidative stress toxin; to expose cells H2O2 at a final concentration of 100μM was mixed 
with culture medium and incubated with cells for 24 hours.  The other toxin cells were 
exposed to an A53T α-synuclein adenovirus transduction; to transduce cells, A53T α-
synuclein adenovirus was mixed with culture medium at a concentration of 200 plaque 
forming units (pfu) / cell and incubated for 24 hours.   
RNA extraction and purification 
N27 cells were cultured in 6-well plates and treated with compounds as described 
above.  RNA was isolated with the use of RNeasy Mini Kit (qiagen, #74104; Valencia, 
CA, USA) according to manufacturer’s instructions.  Extracted RNA pellets were eluted 
in 30 μL of RNase-free H2O. Total RNA was quantified using the ND-1000 Nanodrop 
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and assessed for quality using the ratios: A260/A280 (range: 1.9-2.1) and A260/A230 
(range: 2.0-2.2; if < 2.0, contamination) in addition to the Agilent Biolyzer RNA 6000 
Nano Kit (RNA Integrity Number range: 7.2-8.0).  
RT-qPCR 
Bioanalyzed RNA of good quality was reverse transcribed using 0.1 μg of RNA 
per reaction in a 20 μL reaction.  As a negative control, one reaction without reverse 
transcriptase was performed.  Reverse transcription mix was added to tubes and 
incubated at 25°C for 5 min then 42°C for 10 min then 85°C for 5 min then held at 4°C.  
Reaction mix was iScript Mix and iScript RT (BioRad). Quantitative PCR was performed 
using the primer sets II-XXXI and normalized with β-actin primer set I listed in Table 2.  
Primers were designed using Primer-BLAST (NCBI, Primer-BLAST); all priemrs were 
designed to have a PCR product size between 100bp-200bp and all primer sets have a 
melting temperature (Tm) of 60°C unless otherwise noted in Table 2.  Primer sets were 
obtained from Inveitrogen and eluted to 25 μM stock concentrations inRNAse-free H2O.  
The cDNA template (1uL) was qPCRed with the primers at 200n nM final concentrations 
in 1 X iQ SYBR Green Supermix (BioRad) in a total reaction volume of 50 μL.  Both 
reverse-transcription and qPCR assays were performed on a BioRad iCycler using the 
following program: 94°C for 5 min; (94°C for 30 sec, 60°C for 30 sec, 72°C for 30 sec) 
for 35 cycles; 72°C for 10 min followed by a melt curve.  Relative gene expression was 
determined using the Livak 2^[-ΔΔC(t)] method.   
Western blotting 
N27 cells were cultured in 6-well plates and treated with compounds as described 
above.  Cells were lysed in a dissociation buffer containing 50 mM Tris-HCl, 10 mM 
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NaCl, 0.1% Triton X-100 plus protease inhibitor mixture (Roche).  Protein concentration 
PAGE pre-case gel (BioRad) and transferred to a nitrocellulose membrane. After 
blocking nonspecific binding, membranes were incubated with antibodies to DJ-1 
(1:1000, Millipore), α-synuclein (1:1000, Sigma), Lamp2 (1:1000, AbCam), Nrf2 
(1:1000, Invitrogen) and β-actin (1:2000, Sigma).  Blots were incubated with HRP-
conjugated secondary antibody (1:10,000, Jackson Immuno Research), followed by 
chemiluminescent detection (Perkin Elmer Life Sciences).    
Statistics 
Significance was tested using multivariate ANOVA and the Tukey Honestly 
Significance Difference (HSD) post-hoc tests and Student’s paired T-tests.  Significance 
was set at p < 0.05.  Values are shown as mean ± SE.   
 
Results 
Phenylbutyrate increases expression of DJ-1 and activates oxidative-stress response 
pathways in presence of ROS 
Expression changes of 30 genes known to be rate limiting enzymes or regulatory 
genes in essential cellular pathways were evaluated in N27 rat dopamine neurons when 
cells were treated with drug and cellular stresses.  I examined gene expression changes 
when cells were treated with phenylbutyrate, oxidative stress or mutant α-synuclein 
alone.  Additionally I examined gene expression changes when cells were pre-treated 
with phenylbutyrate for 48 hours and then exposed to oxidative stress or mutant α-
synuclein stresses for 24 hours.  Total RNA was extracted from cultured N27 cells treated 
with above conditions.  Extracted RNA samples were quantified and RNA quality was 
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assessed with a Biolyzer.  RNA quality is reported by an RNA Integrity Number (RIN) 
ranging from 0 to 10, in which any RIN above 7 is considered high quality.  The RNA 
samples used for the RT-qPCR screen had an average RIN of 7.8 ± 0.1.  The RNA was 
then converted into cDNA templates and the differential expression changes of the genes 
in Table 2 were measured using quantitative PCR.  
Results of the RT-qPCR screen show that phenylbutyrate treatment alone was 
sufficient to significantly increase expression of DJ-1 (55-fold), Nrf2 (60-fold), GCL 
(2.5-fold) and PRDX2 (12-fold) (Fig. 28).  We have previously reported that 
phenylbutyrate can increase expression of DJ-1 and GCL in N27 cells.  We have also 
shown that GCL up-regulation is caused by DJ-1 up-regulation; knockdown of 
endogenous DJ-1 with sh-RNA abolishes GCL up-regulation and neuorprotection from 
phenylbutyrate (Zhou et al, 2011).   
The qPCR results support accepted mechanistic pathways of oxidative stress 
response in dopamine neurons.  The Nrf2 Antioxidant Response Element (ARE) pathway 
is the primary cellular defense against the cytotoxic effects of oxidative stress.  Under 
non-oxidative stress conditions, Nuclear factor-like 2 (Nrf2) is kept in the cytoplasm by 
Kelch-like-ECH-associated protein 1 (Keap1).  When bound to Keap1, Nrf2 is targeted 
and ubiquitinated by the E3-Ubiquitin Ligase Cullin3; Nrf2 is then degraded by the 
ubiquitin proteasome system (UPS).  Under non-oxidative stress conditions, Nrf2 has a 
half-life of only 20 minutes (Moi et al, 1994).  DJ-1 protein stabilizes cytoplasmic Nrf2 
and increases its cellular half-life by preventing its binding with Keap1, thereby 
preventing the subsequent ubiquitination of Nrf2 (Clements et al, 2006).  When Nrf2 is 
not ubiquitinated, it builds up in the cytoplasm and translocates into the nucleus.  In the 
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nucleus, Nrf2 forms a heterodimer with a small Maf protein (sMaf) and the heterodimer 
binds to the Antioxidant Response Element (ARE) in the promoter region of many anti-
oxidative genes and initiates their transcription (Itoh et al, 1997).  Excess DJ-1 in the 
cytoplasm results in nuclear targeting of Nrf2 and the subsequent induction of many 
cytoprotective genes including glutamate cysteine ligase (GCL), the rate limiting step in 
glutathione (GSH) synthesis, which is a very powerful endogenous antioxidant (Silos et 
al, 2002).  Additionally, Nrf2 induces transcription of peroxiredoxin 2 (PRDX2), an 
antioxidant enzyme that is involved in eliminating peroxides generated during 
metabolism and is essential for regulating healthy intercellular concentrations of 
hydrogen peroxide.  Additionally, Nrf2 gene expression is also induced by Nrf2 binding 
and works to promote extended protection against oxidative stress through a positive 
expression feedback loop (Thimmulappa et al, 2002); the antioxidant response pathway is 
diagrammed in Figure 29. Phenylbutyrate enhances the endogenous antioxidant response 
element pathway by up-regulating cytoplasmic DJ-1 levels, thereby preventing Nrf2 
degradation and inducing transcription of antioxidant response genes.   
Phenylbutyrate selectively up-regulates the Ubiquitin Proteasome System pathway 
to catabolize α-synuclein oligomers. 
We have shown that phenylbutyrate is sufficient to specifically up-regulate 
oxidative stress response genes in order to protect dopamine neurons from hydrogen 
peroxide toxicity.  At the same time, expression levels of the oxidative stress response 
genes were unchanged in response to transfection with oligomer-forming A53T               
α-synuclein.  However, we have previously shown that DJ-1 can protect neurons from  
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Figure 28: Phenylbutyrate protects dopamine neurons from oxidative stress by up-

























































C: Oxidative Stress Gene: GCL 

















































































































































































Figure 28: Phenylbutyrate protects dopamine neurons from oxidative stress by up-
regulating DJ-1 gene and oxidative stress response genes Nrf2, GCL and PRDX2. 
N27 cells in 6-well plates were treated with 100μM phenylbutyrate for 48 hours (PB) 
then exposed to 100μM H2O2 or 200 pfu/cell A53T α-synuclein adenovirus for 24 hours 
(PB+ H2O2 and PB+A53T).  Additionally, a 6-well plate was exposed to 100μM H2O2 
alone and a 6-well plate was exposed to 200 pfu/cell A53T adenovirus alone (H2O2 and 
A53T).  Gene expression changes were normalized to internal control β-actin and 
compared to gene expression levels in untreated control cells (N27).  A) DJ-1: PB alone 
significantly increases DJ-1 expression (PB: 55-fold).  Additionally, when cells were 
exposed to H2O2 and A53T alone, DJ-1 expression is increased so that DJ-1 can protect 
the cells from these stresses (H2O2: 35-fold and A53T: 45-fold).  Importantly, when cells 
are pre-treated with PB followed by exposure to H2O2 or A53T, DJ-1 expression is 
additive: for PB+ H2O2, expression is increased a total of 300-fold and for PB+A53T, 
expression is increased a total of 200-fold. B) Nrf2:  PB treatment significantly increased 
Nrf2 expression (60-fold).  Additionally, cells exposed to H2O2 alone increased Nrf2 
expression 95-fold to protect against oxidative stress.  Pre-treatment with PB followed by 
exposure to H2O2 dramatically increased Nrf2 expression to better protect against 
oxidative stress:  PB+ H2O2, expression is increased a total of 500-fold.  On the other 
hand, cells exposed to A53T toxin alone had a significant reduction in Nrf2 expression 
(30% of gene expression seen in untreated cells).  C) GCL:  PB treatment alone 
significantly increased GCL expression (PB: 2.5-fold) as did treatment with H2O2 alone 
(H2O2: 7.5-fold).  Pre-treatment with PB followed by H2O2 exposure significantly 
increased GCL expression to a total of 27-fold that of untreated controls enhancing GCL 
protection against oxidative stress.  When cells were exposed to A53T or PB+A53T, 
GCL expression was unaffected.  D)  PRDX2:  When cells are treated with PB alone and 
when cells are exposed to H2O2 alone, expression of PRDX2 was significantly increased 
(PB: 12-fold and H2O2: 8-fold).  Pre-treatment with PB followed by H2O2 exposure did 
not have an additional effect on PRDX2 expression levels.  Also, when cells were 
exposed to A53T or PB+A53T, PRDX2 expression was unaffected (The results are 





cell death caused by expression of mutant α-synuclein by activating the Hsp70 chaperone 
pathway.  In this study, the differential expression patterns were examined for a number  
of chaperone genes as well as genes reported to be involved in protein catabolism via the 
ubiquitin proteasome system (UPS) pathway.   The genes screened in this study are listed 
in Table 2.   There were significant changes in expression in the SIAH1 E3-Ubiquitin 
Ligase gene, and in the Hsc70, iHsp70 and Hsp40 chaperone genes.  The UPS protein 
catabolism pathway is specifically up-regulated by phenylbutyrate to protect dopamine 
neurons from toxic A53T α-synuclein oligomers.  The degradation of cellular proteins is 
a highly complex, temporally controlled and tightly regulated process that plays major 
roles in a variety of basic cellular pathways.  With the multitude of protein substrates 
targeted for degradation and the number of processes involved, it is not surprising that 
aberrations in the UPS pathway are implicated in the pathogenesis of several diseases.  
Many forms of familial Parkinson’s disease are caused by mutations in genes known to 
be key components in the UPS pathway.  Since dysfunction of the UPS results in familial 
Parkinson’s disease, the proper function of the system is essential for neuroprotection.  
Therefore, activation of the UPS system in the presence of toxic α-synuclein oligomers is 
a promising therapeutic target. 
Degradation of a protein by the UPS involves a number of distinct successive 
steps.  A protein can be targeted for degradation in the UPS if it is misfolded, abnormally 
aggregated or if its cellular function is no longer necessary.  The classical function of 
chaperone proteins is to facilitate protein folding, inhibit misfolding and prevent 
aggregation.  However, not every attempt to properly re-fold a protein or prevent 





Figure 29:  Nrf2 Antioxidant Response Element pathway 
The Nrf2 ARE pathway controls the expression of genes whose protein products are 
involved in the elimination of reactive oxygen species.  Phenylbutyrate enhances the 
endogenous antioxidant response element pathway by up-regulating cytoplasmic DJ-1 
levels, thereby preventing Nrf2 degradation and inducing gene expression of a number of 




proteins to cellular degradation machinery for destruction (Hohfeld et al, 2001).  
Chaperones recognize substrate proteins that need to be degraded and direct them to a 
protein-specific E3 Ubiquitin Ligase.  In an ATP-dependent series of reactions, the E3 
Ubiquitin ligase performs the covalent bonding of ubiquitin proteins to the protein 
substrate.  The bound ubiquitin proteins act as a flag for transport of the substrate protein 
to a 26S proteasome complex within the cell.  The target protein is then reduced to 
peptides within the proteasome leading to the release of the free and reusable ubiquitin, a 







































Figure 30:  Ubiquitin proteasome system for protein catabolism 
Protein degradation through the ubiquitin proteasome system (UPS) is the major pathway 
of non-lysosomal catabolism of intercellular proteins.  It plays important roles in a variety 
of fundamental cellular processes, including degradation of misfolded or aggregated 
proteins.  The central element of this pathway is the linkage of ubiquitin to targeted 
proteins which are then recognized and degraded by the 26S proteasome.  Disruption of 
this system leads to disruption of cellular homeostasis and can lead to a number of 
diseases, including Parkinson’s disease.  Adapted from Willis et al., 2010. 
 
Molecular chaperones—specifically Heat Shock Proteins—have a variety of 
essential cellular functions.  The main roles of Heat Shock Proteins are to inhibit protein 
aggregation, bind non-native proteins, promote folding to the native state and, as a last 
resort, interact with proteases to eliminate protein aggregates and proteins that fail to 
attain their native confirmation (Hohfeld et al, 2001).  We have previously reported that 
the heat shock protein iHsp70 is significantly up-regulated when cells are transfected 
with A53T α-synuclein (Zhou et al, 2011).   In this study we found that in addition to an 



























Figure 31: Phenylbutyrate protects N27 cells from cellular toxicity by up-regulating 
chaperone genes and the SIAH3 protein targets α-synuclein for UPS degradation 
 N27 cells in 6-well plates were treated with 100μM phenylbutyrate for 48 hours (PB) 
then exposed to 100μM H2O2 or 200 pfu/cell A53T α-synuclein adenovirus for 24 hours 
(PB+ H2O2 and PB+A53T).  Additionally, a 6-well plate was exposed to 100μM H2O2 
alone and a 6-well plate was exposed to 200 pfu/cell A53T adenovirus alone (H2O2 and 
A53T).  Gene expression changes were normalized to internal control β-actin and 
compared to gene expression levels in untreated control cells (N27).  A, B and C) iHsp70, 
Hsc70 and Hsp40: PB alone significantly increases both iHsp70 and Hsc70.  
Additionally, when cells were exposed to A53T alone, expression of iHsp70, Hsc70 and 
Hsp40 are significantly increased so that the chaperone proteins can facilitate catabolism 
of aggregated A53T α-synuclein.  Importantly, when cells are pre-treated with PB 
followed by exposure to A53T, expression for iHsp70, Hsc70 and Hsp40 is additive:  PB 
enhances the intrinsic UPS protein catabolism mechanism in cells.  D) SIAH1:  
expression of SIAH1 is significantly up-regulated when cells are exposed to A53T α-
synuclein, but the expression of SIAH1 is unchanged when cells are treated with PB or 
when cells are exposed to H2O2.  SIAH1 E3 ubiquitin ligase specifically targets α-
synuclein for catabolism via the UPS (the results are shown as the means ± SEM; *, p < 
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regulation in the chaperone genes Hsc70 and Hsp40 in response to A53T α-synuclein 
(Fig. 31).  Additionally, the results show Hsc70 and Hsp40 are significantly up regulated 
when cells are treated with hydrogen peroxide.  This is because exposure to oxidative 
stress changes the cytoplasmic pH and will alter the native confirmation of a number of 
cellular proteins.  The chaperone proteins are up-regulated in order to reinstate proper 
folding or to facilitate proteasomal degradation of non-native proteins.  Importantly, 
treatment with phenylbutyrate alone significantly up-regulates iHsp70 and Hsc70; also, 
pre-treatment with phenylbutyrate enhances up-regulation of the chaperone genes when 
cells are stressed with both hydrogen peroxide and A53T α-synuclein (Fig. 31).  
Another essential step in protein degradation via the proteasome is the 
ubiquitination of the target substrate by its protein-specific E3 Ubiquitin Ligase.  The 
SIAH1 gene is a member of the seven in absentia homolog (SIAH) family of E3 ubiquitin 
ligases.  SIAH1 has been reported to co-localize with α-synuclein in Lewy bodies found 
in the substantia nigra of Parkinson’s disease patients (Liani et al, 2004).  It has been 
proposed that α-synuclein is a substrate target of SIAH1 (Lee et al, 2007).  The results of 
this screen show that SIAH1 expression is significantly up-regulated in the presence of 
A53T α-synuclein, but its expression is unaffected by exposure to oxidative stress       
(Fig. 31).  This result confirms that although exposure to oxidative stress within the cell 
will change the confirmation and promote aggregation of a number of proteins, the 
SIAH1 E3 ubiquitin ligase specifically targets α-synuclein for proteasomal degradation. 
These findings indicate that phenylbutyrate treatment enhances the cell’s intrinsic ability 
to manage both misfolded proteins as well as protein aggregates by up-regulating the 
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expression of chaperone proteins and that SIAH1 E3 ubiquitin ligase specifically 
ubiquitinates α-synuclein for degradation. 
Phenylbutyrate selectively up-regulates the Lysosome/Exosome protein elimination 
pathway to enhance α-synuclein clearance 
In addition to the ubiquitin-mediated proteasomal degradation pathway, the cell 
also utilizes a complex mechanism of elimination and clearance of misfolded or 
aggregated proteins.  The primary pathway of protein elimination in eukaryotic cells is 
the lysosomal trafficking and exosomal export pathway.  Intercellular components that 
have been sequestered by autophagy are either degraded in lysosomes or eliminated from 
the cell in exosomes.  Proteins tagged for lysosomal degradation or exosomal export are 
sorted into Multivesicular Bodies (MVBs).  Protein sorting into MVBs is mediated by a 
set of multiprotein complexes that are associated with the endosomal membrane which 
are collectively referred to as ESCRT (endosomal sorting complex required for transport) 
I-III family of proteins (Sorkin et al, 2009).  Exosome biogenesis begins with formation 
of Interluminal Vesicles (ILVs) through inward budding of endosomes to form MVBs.  
The MVBs fuse with the outer cell membrane to release their cargo of ILVs—now called 
exosomes—to the extracellular environment.  When the exosomes leave the cell of 
origin, in this case the midbrain dopamine neurons, they enter the cerebrospinal fluid 
(CSF) and eventually the bloodstream (Fig. 32).  Both Vamp2 and Lamp2 have been 
detected in blood plasma exosomes and these proteins have become widely used markers 






Figure 32:  Lysosome-Exosome pathway for protein elimination 
Early endosomes—EE— carrying endocytosed plasma-membrane proteins and vesicles 
carrying misfolded and aggregated cytoplasmic proteins fuse with the late endosome, 
transferring their cargo to the multivesicular body (MVB).  Proteins to be degraded are 
incorporated into inter luminal vesicles (ILVs) that bud into the interior of the 
multivesicular body containing many ILVs.  Fusion of an ILV with a lysosome releases 
the ILVs into the lumen of the lysosome; there the entire ILV can be degraded in a 
process known as lysosomal degradation.  Alternatively, ESCRT transport proteins can 
facilitate fusion and release of ILVs (now referred to as exosomes) to the extracellular 









































Proteins such as Vamp2 (vesicle associated membrane protein 2) and Lamp2 
(lysosome associated membrane protein 2) are incorporated into the membranes of ILVs. 
Vamp2 and Lamp2 interact with ESCRT complexes and are essential for the fusion of the 
lysosome/exosome protein elimination pathway including the expression of VAMP2 and 
LAMP2 (for a complete list of genes screened, see Table 2).  Our results indicate that of 
the lysosomal/exosomal genes screened, phenylbutyrate is sufficient to selectively up-
regulate VAMP2 and LAMP2.  Additionally, when cells are transfected with mutant 
A53T α-synuclein both VAMP2 and LAMP2 are significantly up-regulated.  These 
results indicate that in the presence of toxic α-synuclein aggregates, the cell will activate 
the lysosome/exosome pathways in addition to the UPS pathway in order to eliminate 
toxic proteins from the neuron.  Importantly, pre-treatment of cells with phenylbutyrate 
significantly enhances the up-regulation of VAMP2 and LAMP2 when cells are stressed 
with abnormal α-synuclein aggregation.   Our results also indicate that LAMP2 
expression is significantly up-regulated when cells are treated with hydrogen peroxide 
and phenylbutyrate enhances this up-regulation.  When cells are exposed to oxidative 
stress, cytoplasmic proteins can aggregate or change secondary structure.  Presumably, 
the LAMP2 gene is up-regulated in order to facilitate lysosomal degradation of these 
misfolded or aggregated proteins and phenylbutyrate increases this activation (Fig. 33). 
Our results indicate that the lysosome/exosome protein elimination pathway is 
utilized in the processing of toxic α-synuclein oligomers and other misfolded or 
aggregated proteins caused by oxidative stress.  Dysfunction of this protein elimination 
pathway would result in a buildup of intercellular protein aggregates and pathogenesis of 
Parkinson’s disease.  These results validate the recent epidemiological observation that  
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Figure 33 :  Phenylbutyrate up-regulates the VAMP2 and LAMP2 genes and 
activates the lysosome-exosome protein elimination pathway 
N27 cells in 6-well plates were treated with 100μM phenylbutyrate for 48 hours (PB) 
then exposed to 100μM H2O2 or 200 pfu/cell A53T α-synuclein adenovirus for 24 hours 
(PB+ H2O2 and PB+A53T).  Additionally, a 6-well plate was exposed to 100μM H2O2 
alone and a 6-well plate was exposed to 200 pfu/cell A53T adenovirus alone (H2O2 and 
A53T).  Gene expression changes were normalized to internal control β-actin and 
compared to gene expression levels in untreated control cells (N27).  A) VAMP2:    
PB alone significantly increases VAMP2 expression (PB: 3.5-fold).  Additionally, when 
cells were exposed to A53T alone, VAMP2 expression is increased so that the α-
synuclein aggregates can be eliminated via lysosomal degradation or exosomal export 
(A53T: 100-fold).  Importantly, when cells are pre-treated with PB followed by exposure 
to A53T, VAMP2 expression is additive indicating that PB treatment enhances the 
lysosome-exosome protein elimination pathway: for PB+A53T, expression is increased a 
total of 200-fold. B) LAMP2:  PB treatment significantly increased LAMP2 expression 
(35-fold).  Additionally, when cells were exposed to A53T alone, LAMP2 expression is 
increased so that the α-synuclein aggregates can be eliminated via lysosomal degradation 
or exosomal export (A53T: 120-fold).  Also, cells exposed to H2O2 alone increased 
LAMP2 expression 5-fold to eliminate proteins that are misfolded due to change in 
cytoplasmic pH.  Importantly, pre-treatment with PB followed by exposure to H2O2 or 
A53T dramatically increased LAMP2 expression (PB+ H2O2: LAMP2 expression is 
increased to a total of 180-fold; PB+A53T: LAMP2 expression is increased to a total of 
450-fold).  This result confirms that phenylbutyrate enhances the lysosome-exosome 
protein elimination pathway to remove aggregated α-synuclein and other misfolded 
























































































































patients and relatives of patients with Gaucher’s disease present with a higher incidence 
of Parkinson’s disease compared to the general population (Sidransky E., et al. 2009).  
Gaucher’s disease is a common lysosomal disease caused by a mutation in the lysosomal 
enzyme glucocerebrosidase or GBA.  Loss of enzymatic function of GBA results in the 
inability of lysosomes to properly degrade proteins and fatty acids within the lysosome 
and eventually causes lysosomal failure.  Under normal conditions, activation of the 
lysosomal elimination pathway should up-regulate GBA enzyme expression in order to 
facilitate lysosomal degradation.  Our results show that expression of GBA is enhanced 
when cells activate the lysosomal degradation pathway; GBA is up-regulated as a result 
of both oxidative stress and mutant A53T α-synuclein (Fig. 34).  These findings provide a 
molecular confirmation of the keen clinical observation linking incidence of the 
lysosomal disorder Gaucher’s disease and Parkinson’s disease. 
Increased gene expression results in higher cellular protein levels 
Results from the RT-qPCR expression screen indicated that out of the 30 essential 
cellular pathway genes screened for differential expression patterns, only 11 of the genes 
had significant changes in gene expression as a result of phenylbutyrate treatment and 
cellular stresses (DJ-1, NRF2, GCL, PRDX2, SIAH1, Hsc70, iHsp70, Hsp40, LAMP2, 
VAMP2  and GBA).  In order to verify that these dramatic changes in mRNA levels are 
converted into increases in cellular protein levels of these gene products, proteins from 
whole cell lysates were isolated from the treated N27 cells and protein content was 
analyzed.  The DJ-1 protein levels mirror the mRNA levels detected by RT-qPCR 
analysis.  The DJ-1 levels were significantly increased when cells were treated with 
phenylbutyrate treatment, and when cells were pre-treated with phenylbutyrate followed 




Figure 34:  Lysosomal enzyme GBA is up-regulated in response to oxidative stress 
and α-synuclein aggregation 
N27 cells in 6-well plates were treated with 100μM phenylbutyrate for 48 hours (PB) 
then exposed to 100μM H2O2 or 200 pfu/cell A53T α-synuclein adenovirus for 24 hours 
(PB+ H2O2 and PB+A53T).  Additionally, a 6-well plate was exposed to 100μM H2O2 
alone and a 6-well plate was exposed to 200 pfu/cell A53T adenovirus alone (H2O2 and 
A53T).  Gene expression changes were normalized to internal control β-actin and 
compared to gene expression levels in untreated control cells (N27).  Patients with the 
lysosomal disorder Gaucher’s disease—caused by a mutation in the lysosomal enzyme 
encoded by the GBA gene—have a higher incidence of Parkinson’s disease.  The results 
from the RT-qPCR screen of the GBA gene show that when cells are exposed to 
oxidative stress and A53T α-synuclein, the GBA gene is significantly up-regulated.  
Since the lysosomal degradation pathway is activated under these stresses, loss-of-
function mutations in GBA would result in the inability for the neuron to eliminate the 
stresses via lysosomal degradation and would cause Parkinson’s disease (the results are 





























































previous findings and underscores the concept that treatment with phenylbutyrate is 
sufficient to up-regulate DJ-1 expression and protein levels and protect dopamine 
neurons from cellular toxicity (Fig. 35A). The protein levels for Nrf2 also mimic the 
mRNA expression levels seen from the RT-qPCR screen.  As expected, when cells are 
treated with H2O2 the oxidative stress response protein Nrf2 levels are increased.  Nrf2 
levels are further up-regulated when cells are pre-treated with phenylbutyrate then 
exposed to oxidative stress.  These results indicate phenylbutyrate treatment can enhance 
the cell’s ability to protect against oxidative stress (Fig. 35B).   
The amount of intercellular α-synuclein oligomer was also measured. As 
expected, untreated N27 cells had no α-synuclein oligomers and when cells were treated 
with phenylbutyrate alone, no α-synuclein oligomers developed.  However, when cells 
were exposed to oxidative stress, the intercellular pH changed and the native form of 
many proteins was disrupted and many proteins began to form aggregates, including α-
synuclein.  Our results show that when cells are exposed to oxidative stress there is an 
increase in the amount of intercellular α-synuclein oligomers.  Additionally, as expected, 
when cells were transfected with A53T mutant α-synuclein, there was also a significant 
increase in intercellular α-synuclein oligomers.  Importantly, when cells are pre-treated 
with phenylbutyrate, the levels of intercellular α-synuclein oligomers is drastically 
reduced.  This finding emphasizes the neuroprotective effects of phenylbutyrate 
treatment; phenylbutyrate up-regulates pathways within the cell to catabolize α-synuclein 
aggregates without promoting protein aggregation itself (Fig. 35C).   
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Figure 35:  Western blot analysis of intercellular proteins confirms gene expression 
changes caused by phenylbutyrate treatment.  
N27 cells in 6-well plates were treated with 100μM phenylbutyrate for 48 hours (PB) 
then exposed to 100μM H2O2 or 200 pfu/cell A53T α-synuclein adenovirus for 24 hours 
(PB+ H2O2 and PB+A53T).  Additionally, a 6-well plate was exposed to 100μM H2O2 
alone and a 6-well plate was exposed to 200 pfu/cell A53T adenovirus alone (H2O2 and 
A53T).  Protein levels were analyzed with Western blot and incubated with primary 
antibodies to DJ-1, Nrf2, α-synuclein and Lamp2. Blots were incubated with HRP-
conjugated secondary antibody followed by chemiluminescent detection and quantitative 
analysis.  Protein levels were normalized to intercellular β-actin (the results are shown as 
the means ± SEM; *, p < 0.05; **, p < 0.01; n = 6).  
 
Finally, the intercellular levels of the lysosome and exosome marker LAMP2 
were analyzed.  The intercellular protein levels of Lamp2 mimicked the mRNA levels  
detected with RT-qPCR analysis when cells were exposed to phenylbutyrate and H2O2 
stresses.  Phenylbutyrate treatment significantly increased intercellular Lamp2 protien 
levels and pre-treatment of phenylbutyrate followed by exposure to oxidative stress up-






















































































































exposed to oxidative stress to activate the lysosomal degradation proteins that aggregate 
due to the intercellular pH change and phenylbutyrate treatment enhances lysosomal 
activation.  On the other hand, our RT-qPCR results show a highly significant increase in 
LAMP2 expression when cells are exposed to A53T mutant α-synuclein.  However, there 
does not seem to be an increase in intercellular Lamp2 protein levels.  When cells are 
exposed to abnormal α-synuclein aggregates, LAMP2 expression is significantly 
increased to activate the exosomal export pathway in order to clear the α-synuclein 
aggregates from the neurons.   
  Therefore, LAMP2 transcription and translation are up-regulated with 
phenylbutyrate and A53T α-synuclein, and simultaneously the exosome export system is 
activated.  The Lamp2 protein is an exosome marker and is being released from the 
neurons in the exosomes containing α-synuclein, therefore, and we find that the 
intercellular Lamp2 levels remain unchanged (Fig. 35D).  The change protein levels of 
differentially expressed genes as a result of phenylbutyrate treatment validate the RT-
qPCR findings and further elucidate mechanistic pathways of neuroprotection of 
phenylbutyrate.  
Discussion 
 We have reported that treatment with the HDACi phenylbutyrate is sufficient to 
significantly up-regulate the protein levels of neuroprotective protein DJ-1 in rat 
dopamine neurons.  By a mechanism of up-regulation of DJ-1, phenylbutyrate treatment 
can protect dopamine neurons from cellular toxicity caused by both exposure to oxidative 
stress and exposure to toxic α-synuclein aggregation.  We have also shown that in our 
transgenic mouse model of progressive diffuse Lewy body disease, treatment with 
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phenylbutyrate in the drinking water can prevent development of disease.  Transgenic 
mice treated with phenylbutyrate for 12 weeks had significantly higher levels of DJ-1 in 
the brains, resulting in significantly reduced brain α-synuclein oligomer formation 
compared to untreated transgenic mice.  The mice treated with phenylbutyrate also 
showed significantly lower age-dependent cognitive and motor decline compared to 
untreated transgenic animals.  
 
Additionally, the results indicate that the significant reduction in brain                 
α-synuclein oligomers seen in transgenic mice treated with phenylbutyrate was a result of 
an up-regulation of an intrinsic clearance mechanism of α-synuclein from the brain to the 
plasma.  We know this because the transgenic mice express a human mutant form of       
α-synuclein only in the brain neurons.  Therefore, any human α-synuclein detected in the 
plasma is known to have been cleared from the brain to the plasma.  Using a human-
specific α-synuclein antibody, we have shown that there is human α-synuclein in the 
plasma of transgenic mice indicating a mechanism of mobilization from the brains.  
Importantly, transgenic mice treated with phenylbutyrate had higher levels of human and 
mouse α-synuclein in the plasma.  These results, taken together with the reduced levels of 
brain α-synuclein oligomers in mice treated with phenylbutyrate reveal that 
phenylbutyrate is working to activate a clearance mechanism to remove toxic proteins 
from the dopamine neurons thereby preventing the progression of disease.  Additionally, 
we have shown that Parkinson’s patients treated with 16 grams of phenylbutyrate a day 
have significantly increased levels of plasma α-synuclein compared to baseline plasma α-
synuclein levels.  This reveals that phenylbutyrate treatment in humans also activates 
mechanisms of α-synuclein clearance from the brain to the plasma.  
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To better understand the protection mechanisms that dopamine neurons use to 
reduce oxidative stress and remove toxic protein aggregates and to understand how 
phenylbutyrate treatment is activating these mechanisms, I performed a gene expression 
screen.  The differential expression patterns of 30 genes were analyzed using RT-qPCR 
analysis to determine any gene expression changes when cells were exposed to 
phenylbutyrate or cellular stresses alone or when cells were pre-treated with 
phenylbutyrate then exposed to cellular stresses.  We examined the effects of the two 
cellular stresses hallmark to Parkinson’s disease development: oxidative stress and 
abnormal α-synuclein aggregation.  Differential expression patterns of 30 regulatory 
genes that are essential in a number of cellular protection pathways were screened; these 
pathways included oxidative stress regulation pathways, protein catabolism pathways 
(including the ubiquitin-proteasome pathway and the lysosome/exosome vesicle 
trafficking pathway), mitochondrial regulation pathways, apoptosis pathways and nerve 
growth pathways. 
 Results from the RT-qPCR expression screen indicated that out of the 30 essential 
cellular pathway genes screened, only 11 of the genes had significant changes in gene 
expression as a result of phenylbutyrate treatment and cellular stresses.  The genes that 
showed differential expression were DJ-1, NRF2, GCL, PRDX2, SIAH1, HSC70, HSP70, 
HSP40, LAMP2, VAMP2 and GBA.  These genes are responsible for regulation of 
oxidative stress homeostasis, ubiquitin-proteasome degradation, lysosomal catabolism 
and exosomal export pathways.  These findings further reveal the variety of pathways and 
genes that can be involved in the pathogenesis of Parkinson’s disease.  Additionally, I 
have shown that treatment with phenylbutyrate is non-toxic to dopamine neurons and can 
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significantly activate these pathways and reduce the cellular stressors that cause neuronal 
death.  Therefore, treatment with phenylbutyrate is a promising potential therapy to stop 
the progression of Parkinson’s disease by up-regulation of DJ-1 and activating the 






EXERCISE UP-REGULATES DJ-1 AND PREVENTS PROGRESSION OF 
PARKINSON’S DISEASE IN A TRANSGENIC MOUSE MODEL 
Introduction 
Parkinson’s disease is caused by the loss of midbrain dopamine neurons due to 
oxidative stress, abnormal protein aggregation, and genetic predisposition. Because 
Parkinson’s disease is a progressive movement disorder, patients suffer from increasing 
difficulty in moving.  Exercise and physical therapy are commonly recommended by 
clinicians with the end goal of retaining the ability to move and prevent the decline of 
muscle function.  Several clinical trials have shown that exercise can improve the 
cognition, balance and motor performance in people with Parkinson’s disease (Cruise et 
al, 2011; Dibble et al, 2009; Fisher et al, 2008).  Additionally, recent studies indicate 
some evidence that in drug-induced and transgenic Parkinson’s disease animal models, 
exercise can partially protect dopamine neurons from neurotoxicity (Gerecke et al, 2009; 
Gorton et al, 2010; Tajiri et al, 2010; Tillerson et al, 2003; Wu et al, 2011; Zigmond et al, 
2009).  However, it had yet to be studied whether exercise can up-regulate the 
neuroprotective gene DJ-1 and thereby reduce oxidative stress and abnormal protein 
aggregation and prevent progressive decline of motor and cognitive function in a 
progressive model of Parkinson’s disease.  We previously had reported that the drug 
phenylbutyrate can up-regulate the neuroprotective gene DJ-1, reduce neurotoxicity and 
improve behavioral decline in our transgenic mouse model of Parkinson’s disease.  We 
have also observed in human clinical trials that plasma DJ-1 levels are highly variable 
from person-to-person and from week-to-week.  Since plasma DJ-1 levels can fluctuate 
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in humans, it is reasonable to predict that DJ-1 expression may be controlled by 
environmental factors such as level of activity.  In previous transgenic mouse studies, the 
mice in both the phenylbutyrate group and the control group were highly sedentary in 
their cages.  Therefore, I hypothesize that the differences in plasma DJ-1 levels of the 
human participants studied was caused by differences in activity levels.  If my hypothesis 
is correct it would help explain the significant normalized peak in plasma DJ-1 levels 
seen in humans between mid-December and early-January—I refer to this unexpected 
trend as the “holiday phenomenon.”  If this is the case, than exercise could be an 
inexpensive and effective therapy for Parkinson’s disease through a mechanism of up-
regulation of the neuroprotective gene DJ-1.  
The studies described in this chapter were designed to test the hypothesis that 
regular aerobic exercise is sufficient to up-regulate DJ-1 expression in wild-type mice.  
Additionally, I observed the capability of DJ-1 knock-out mice to perform voluntary 
exercise compared to WT littermates to determine whether DJ-1 function is required for 
performing endurance exercise.  Finally, I tested whether running wheel exercise can 
reduce brain α-synuclein aggregation and improve motor and cognitive function in our 
Y39C transgenic model of progressive Parkinson’s disease.  
Study design and methods 
Running wheel exercise in mice 
All animal procedures have been approved by the Institutional Animal Care and Use 
Committee (IACUC) at the University of Colorado Denver. Adult wild type FVB/N mice 
(4-6 months old) were trained to use cage mounted running wheel (12 cm in diameter) for 
one week.  Animals were housed individually in each cage and daily running distances 
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were recorded through odometer. As a non-exercise control, a group of age matched wild 
type mice received locked, non-functioning running wheels in their cages.  In a separate 
study, a group of 6 adult DJ-1 genetic knock-out mice from the C57BL/6 strain were 
trained to use cage mounted running wheels.  As a control, a group of six wild-type 
C57BL/6 were housed individually and trained to use a cage-mounted running wheel.  
Daily running distances for each mouse for two weeks were recorded with an odometer.  
Additionally, I used our Y39C human α-synuclein transgenic mouse model, which has 
been described previously.  I assessed 12-month old transgenic mice for their ability to 
exercise in running wheel for one week.  I randomly divided transgenic into exercise and 
non-exercise groups according to running distance in the first week.  Running group had 
free access to running wheel in their cages for three months, while non-exercise group 
received blocked non-functioning running wheel in their cage.  Weekly running distances 
were recorded using odometer for each animal.    
Endurance Rotarod test 
Mice were tested for their ability to run on a 3-cm diameter rotating rod (Rotarod) at 
speeds ranging from 3 to 33 rpm.  Before the test, mice were trained
 
to remain on the 
Rotarod at 3 rpm.  During 5 testing days, mice were placed on the rotating rod at one of 
preset
 
speeds for 5 minute endurance trial.  Each animal received 3 trails with 5 minute 
rest interval between trials.  The time the mice spent on the
 




Morris water maze test 
Spatial learning was assessed using the
 
Morris water maze.  The maze included a 
circular
 
tank (120 cm in diameter) filled to 10 cm below the edge of
 
the tank with 27°C 
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water that was made opaque by the addition
 
of non-toxic black ink. A circular escape 
platform (10 cm in
 
diameter) was located 1 cm below the surface of the water in
 
a 
constant location in the northwest quadrant of the tank. Mice were first acclimated to the 
maze during three trial habituation
 
sessions.  Each testing session consisted of 4 
consecutive days with four trials per day. The platform was invisible in the pool, and 
mice were
 
allowed to swim for 60 seconds before being returned to the home
 
cage. The 
latency from all training and testing
 
sessions was collected. 
Western blotting  
The mouse brain and muscle tissues were dissected and homogenized in dissociation 
buffer with protease inhibitors. Protein concentration was determined by the BCA 
method.  Fifty µg of protein was separated on 10% SDS-PAGE gel and transferred to a 
nitrocellulose membrane. Blot was probed with antibodies to DJ-1 (1:5000, Chemicon), 
α-synuclein (Syn-1 and LB509, 1:2000, Transduction Laboratories), β-actin (1:4000, 
Sigma), mouse serum albumin (1:2000, Sigma). Blots were incubated with HRP-
conjugated secondary antibody (1:10,000; Jackson Immuno Research), followed by 
chemiluminescent detection.  Protein densities were quantified by ImageJ software after 
scanning into image file and normalized to β-actin or mouse albumin. 
ELISA  
Mouse blood was collected through transcardiac needle with syringe containing 
EDTA as anti-coagulate. The blood was centrifuged at 2000 rpm for 5 min.  After 
centrifugation, the plasma fraction was collected and stored at -80C.  The small portion 
of plasma was used to determine DJ-1 concentration using ELISA kit (CircuLex), 




All experiments were repeated at least three times. Data were analyzed using 
multivariate ANOVA and the Fisher LSD post hoc test and Student’s T-tests. 
Significance was set at p<0.05.  
Results 
Exercise increases DJ-1 levels in muscle and blood of wild-type mice 
I hypothesized that an increase in oxidative stress in the skeletal muscle and brain 
as a result of aerobic exercise will be sufficient to up-regulate DJ-1 in exercising WT 
mice compared to sedentary littermates.  To test this hypothesis, a group of five adult 
wild type “exercise mice” were trained to perform daily exercise in cage-mounted 
running wheels.  As a control, a group of five adult wild-type “sedentary mice” were 
given non-functional running wheels.  The daily running distances were measured using a 
bike odometer attached to the wheels (Fig. 36).   
 
Figure 36: Running wheel and odometer 
Mice were divided into two groups; one group was given cages with functional running 
wheels mounted in the cages, the other group was given locked running wheels which 
would not rotate.  Running totals in the exercise group were measured using a bike 




After 24 hours of acquisition with the running wheel, the mice began the measured 
voluntary exercise in the running wheels.  During the same time period, a group of 6 
adult wild type “non-exercise mice” were caged with running wheels that were locked 
and would not rotate.  Average daily running distance was 2.88 miles with a range of 2-5 
miles per day.   Over the 7 day running period, the running distances of the mice was 
consistent on average.  After one week of exercise, mice were sacrificed and brain, 
muscle and plasma of exercise and non-exercise mice groups were collected for analysis. 
Many exercise studies done in animal models and humans has shown that exercise 
temporarily increases cellular oxidative stress and that prolonged exercise therapy results 
in long-lasting activation of pathways involved in oxidative stress reduction (Hajizadeh 
Maleki et al, 2013; Powers et al, 2008; Urso et al, 2003).  Previously, we have reported 
that exposure to oxidative stress can up-regulate DJ-1 levels and that higher DJ-1 levels 
can reduce neurotoxic α-synuclein aggregation.  Therefore, we examined DJ-1 levels in 
tissues and blood of exercising and non-exercising WT mice.  DJ-1 levels were 
significantly higher in skeletal muscle tissue and in plasma of exercise mice compared to 
non-exercise controls, as measured by Western blot and ELISA, respectively.  We also 
found whole brain DJ-1 levels were higher in exercise mice compared to non-exercise 
controls as measured by Western blot; however, the levels were not significantly different 
(Fig. 37).  The results of this study demonstrate that running wheel exercise can increase 




Figure 37: Running wheel exercise in wild type mice increases DJ-1 expression in 
plasma, muscle and brain 
Ten wild type adult mice were assigned to either an exercise group or a control sedentary 
group—n=5 per group.  After one week of voluntary running wheel exercise, tissues were 
collected for DJ-1 analysis by Western blot (skeletal muscle and brain tissues; normalized 
to β-actin) and ELISA (plasma).  Quantitative data show that muscle and plasma DJ-1 
levels were significantly increased with one week of exercise (p = 0.04 and p = 0.02, 
respectively), although a similar increase in brain DJ-1 levels did not reach significance 
(p = 0.08).      
 
DJ-1 knock-out mice perform significantly less voluntary exercise and have lower 
endurance motor function than WT mice 
Results indicate that one week of voluntary exercise in WT mice is sufficient to 
significantly increase DJ-1 levels in the skeletal muscle and in the blood plasma.   The 
hypothesis is that with exercise, DJ-1 is up-regulated in order to facilitate clearance of 
exercise-induced oxidative stress.  If this hypothesis is correct, DJ-1 genetic knock-out 
mice will not have the capability to eliminate oxidative stress byproducts of exercise and 
will perform less voluntary running than WT littermates.  To test this hypothesis, the 
voluntary running rates of a group of  six DJ-1 genetic knock-out mice was compared to 
the running rates of a group of six WT littermates.  Using the running wheel with bike 
odometer, I measured the average daily running rates of the two groups for two weeks.  
After two weeks of measuring voluntary exercise, our results show that the DJ-1 knock-
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out mice perform significantly less voluntary running than WT mice.  After an initial 
learning period of roughly 4 days, the wild-type mice were running consistently on 
average about 6 miles a day, ranging from 4 to 8 miles per day.  On the other hand, post-
learning running rates of the DJ-1 knock-out mice stayed consistently at only 1 mile per 
day, ranging from 0.6 miles to 1.3 miles per day (Fig. 38). 
 
Figure 38:  DJ-1 knock-out mice and wild type mice average daily running distance 
Six wild type mice and six DJ-1 genetic knock-out mice were incubated in cages with 
mounted running wheels and allowed voluntary exercise for two weeks.  Running 
distances were recorded daily.  Throughout the two weeks, the DJ-1 knock-out mice ran 
on average significantly less than the WT littermates.  At the end of two weeks, the WT 
mice ran an average of six miles a day and the DJ-1 KO mice ran an average of one mile 
a day (p < 0.001; n = 6). 
    
In order to determine whether the drastic differences in voluntary running rates 
were the result of behavioral differences rather than ability to eliminate exercise-induced 
ROS between the two groups, behavioral tests were performed.  The Open Field 
behavioral test uses motion sensors to measure the total number of movements a mouse 
makes while exploring a foreign environment.  This test determined whether DJ-1 knock-
out mice were running less on the running wheels because of reduced interest in the 
foreign object in their cages.  The amount of exploratory movement over 30 minutes 
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between DJ-1 knock-out mice and WT littermates was not significantly different, 
indicating that the differences in voluntary running was not a result of reduced 
exploratory behavior in DJ-1 knock-out mice (Fig. 39). Additionally, the cognitive 
function between the two groups of mice was analyzed using a spatial-learning Morris 
water maze test as previously described.  On average, the two groups of mice were able 
to find a hidden platform equally well over 5 days of testing.   These results verify that 
the two groups of mice have no differences in spatial learning or cognitive function that 
could account for the disparity observed in voluntary running distances (Fig. 40).  
 
 
Figure 39: DJ-1 knock-out mice and wild type mice have no difference in 
exploratory behavior 
The Open Field exploratory test uses motion sensors to measure the total number of 
movements when a mouse is placed into a foreign environment.  The normal behavior of 
mice is to consistently move and explore in a foreign environment; if a mouse has a 
behavioral deficit in the exploratory behavior, they will have reduced exploratory 
movements in a foreign environment.  The mice were given 30 minutes to explore the 
foreign environment.  The average time of three trials for each group is shown.  The 
Open Field test revealed no differences in exploratory behavior between the DJ-1 KO and 

































Figure 40:  DJ-1 knock-out mice and wild type mice have no differences in cognitive 
function 
The cognitive function of DJ-1 KO mice and WT mice were tested using the Morris 
water maze.  Mice were given 60 seconds to find the hidden platform.  The average time 
of four trials for each group are shown.  There was no difference in water maze 
performance between the two groups of mice (n = 6).  
 
Finally, I measured the endurance motor function of the two groups using an 
Endurance Rotarod test in which the length of time the mice are able to stay on a rotating 
rod at different rates of speeds is measured to determine motor function.  I found that at 
very low rates of speed, both groups of mice had the motor function to remain on the 
Rotarod; additionally, at high rates of speed, both groups of mice were unable to stay on 
the Rotarod.  However, interestingly, at moderate rates of speed (20 rotations per minute) 
the DJ-1 knock-out had significantly less latency on the Rotarod (Fig. 41).  As the rates 
of speed increased, the DJ-1 knockout mice reached the limit of their endurance motor 
function before their WT littermates did.  This gap in endurance motor function suggests 





























build-up after prolonged exercise, and they therefore will be able to perform less 
endurance exercise. If DJ-1 is in fact required to eliminate ROS that are generated during 
aerobic exercise, the DJ-1 knock-out mice would not have the ability to reduce exercise-
induced ROS.  Therefore, prolonged exercise in the DJ-1 mice would result in a 
consistent build-up of oxidative stress in the muscle, which would cause the animals pain.  
In this experiment, we observe that the DJ-1 KO mice voluntarily run on the exercise 
wheels for very short periods of time each day.   This finding supports the hypothesis that 
the DJ-1 KO mice will not be able to eliminate exercise-induced ROS, they will reach 
their pain threshold more rapidly and they will perform significantly less voluntary 
exercise compared to WT mice with endogenous DJ-1 levels.   
 
Figure 41:  DJ-1 knock-out mice have lower endurance motor function than wild-
type mice. 
Both groups of mice were tested for endurance motor function using a Rotarod, each day 
with an increased rate of speed.  Mice were allowed to stay on the rotating rod for a 
maximum of 300 seconds.  The average time of three trials for each group is shown.  The 
WT mice had significantly better endurance motor function at 20 rpm compared to DJ-1 































Old Y39C α-synuclein transgenic mice can perform voluntary running  
 
The results have shown voluntary running wheel exercise can increase DJ-1 levels 
in skeletal muscle and plasma of wild type mice and that DJ-1 knock-out mice have 
reduced endurance motor function resulting in a reduced amount of voluntary exercise 
compared to wild-type mice.  Based on these results, I hypothesized that long term 
running wheel exercise in a progressive mouse model of Parkinson’s disease will up-
regulate DJ-1 and lead to neuroprotective effects.  To test the effects of exercise on the 
progression of Parkinson’s disease, I used the Y39C α-synuclein transgenic mouse model 
of progressive diffuse Lewy body disease.  In this model, a mutant form of human          
α-synuclein is expressed under the brain-specific mouse Thy1 promoter.  In the mutant 
form of the protein, a tyrosine at residue 39 is replaced with a cysteine residue which 
readily forms disulfide bonds and promotes α-synuclein aggregation and Lewy body 
formation.  The transgenic mice form age-dependent α-synuclein oligomers in the brain 
and have age-dependent cognitive and motor decline.  The mice begin to develop 
phenotype between 12 and 15 months of age; therefore, we designed experiments to test 
12-month old transgenic mice to perform voluntary running wheel exercise for three 
months.   
As seen in the exercise experiments with wild type, the mice can have variable 
running capacity.  Because of this, I tested 14 transgenic mice for one week in the 
running wheel and measured their daily running distances using the bike odometer.  I 
then assigned the mice into two equal groups according to their ranking of daily running 
distance: an exercise group and a non-exercise group.  Mice in the non-exercise group 
were given access to a running wheel that was locked and would not turn.  Over the three 
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months of the exercise study, weekly running distances for the exercise group were 
recorded and converted to daily distances (Fig. 42).  
Results confirm that over the 3 month exercise period—during the 12 month- to 
15 month phenotype-development period of Y39C transgenic mice—most mice were 
able to keep a consistent daily running distance.  Y39C transgenic mouse #6 (black line) 
showed a reduction in daily running totals from about eight miles per day to about six 
miles per day; Y39C transgenic mice #14 and #13 (brown line and red line, respectively) 
showed a reduction in daily running totals from about five miles per day to about four 
miles per day.  The remainder of the mice ran consistently about two miles a day.  The 
average daily running totals observed over three months in Y39C transgenic mice are 
similar to the average daily running totals observed in wild type mice (average of 2.88 
miles per day; ranging between 2-5 miles per day).  In conclusion, Y39C α-synuclein 
transgenic mice will voluntarily exercise for three months starting at an age of 12 months 
and finishing at an age of 15 months at rates indistinguishable from wild type mice.  
Exercise reduces motor and cognitive decline of α-synuclein transgenic mice 
During the age interval of 12-15 months, the Y39C α-synuclein transgenic mice 
show a significant motor and cognitive decline when compared to non-transgenic mice.  
We have previously reported that phenylbutyrate treatment during this phenotype-
development stage will reduce the motor and cognitive decline the Y39C mice by a 
mechanism of up-regulation of DJ-1 (Zhou et al, 2011).  Additionally, I have shown that 
exercise up-regulates DJ-1 in wild-type mice (Fig. 37).  Therefore, my hypothesis is that 
exercise intervention will reduce the motor and cognitive decline seen in sedentary Y39C 




Figure 42:  Y39C α-synuclein transgenic mice performed daily running wheel 
exercise for three months 
A group of seven Y39C transgenic mice, 12-months of age, were trained to perform 
voluntary running wheel exercise.  Daily running distances were recorded with a bike 
odometer and averaged for each week.  Data show mice continued voluntary running 
exercise for 12 weeks, and most mice kept relatively steady daily running distances 
throughout the 12-week period. 
 
An endurance Rotarod test was used to measure the motor function of mice after 6 
and 12 weeks of exercise intervention.   After six weeks of voluntary exercise, the 
exercise group showed significantly improved motor function: the exercise group was 
able to stay on the Rotarod rotating at 26 rmp for an average of 128 seconds while the 
non-exercise group was only able to stay on for an average of 48 seconds (Fig. 43A).  
After 12 weeks of voluntary exercise, the 15-month-old exercise group still showed 
significantly improved motor function compared to the non-exercising transgenic mice:  
at 26 rpm, the exercise group was able to stay on the Rotarod on average 102 seconds 
while the non-exercising group was only able to on for an average of 37 seconds (Fig. 
43B).  The endurance Rotarod behavioral test suggests that exercise intervention can 




Figure 43:  Running wheel exercise improved motor function inY39C transgenic 
mice 
The 12-month-old transgenic mice were divided into Exercise and Non-Exercise groups.  
Exercise mice had access to a cage mounted running wheel and Non-exercise mice had 
access to a locked running wheel that would not rotate.  At 6 and 12 weeks of voluntary 
exercise, all mice were tested for endurance motor function using a Rotarod; each day 
rotating at an increase rate of rotation.  Mice were allowed to stay on the rotating rod for 
a total of 300 seconds.  The data shown is the average duration on the Rotarod of three 
trials for each group.  After 6 and 12 weeks of exercise the Exercise group had 
significantly longer duration on the Rotarod at 26 rpm than the Non-Exercise group (**, 
p < 0.01; *, p < 0.05; n = 7).  
 
In addition to motor decline, Y39C α-synuclein transgenic mice show an age 
dependent cognitive decline as measured by Morris water maze; my hypothesis is that 
exercise intervention starting at 12 months will reduce the cognitive decline characteristic 
of old transgenic mice.  To test this hypothesis, I used the Morris water maze test for 
cognitive function after 6 and 12 weeks of exercise intervention.  After six weeks of 
running wheel exercise, the exercise group was able to locate a hidden platform 
significantly faster than the non-exercise group on Day 4 of training (28 seconds on 
average for the exercise group compared to 40 seconds on average for the non-exercise 
group) and on Day 5 of training (23 seconds on average for the exercise group compared 
to 33 seconds on average for the non-exercise group) (Fig. 44A). Additionally, results 
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show that after 12 weeks of exercise intervention, old transgenic mice also performed 
significantly better on the Morris water maze test than did sedentary 15-month old 
transgenic mice. On Day 5 of training, the exercise group took an average of 30 seconds 
to find the hidden platform compared to an average of 39 seconds for the non-exercise 
group (Fig. 44B).  This data confirms that exercise intervention during phenotype-
development stage can reduce the cognitive decline expected in Y39C α-synuclein 
transgenic mice.   
 
 
Figure 44:  Running wheel exercise improved cognitive function in Y39C transgenic 
mice 
The 12-month-old transgenic mice were divided into Exercise and Non-Exercise groups.  
Exercise mice had access to a cage mounted running wheel and Non-exercise mice had 
access to a locked running wheel that would not rotate.  At 6 and 12 weeks of voluntary 
exercise, all mice were tested for cognitive function using a Morris water maze.  Mice 
were given 60 seconds to find a hidden platform in opaque water.  The average time of 
four trials for each group is shown.  After 6 and 12 weeks of exercise intervention, the 
exercise group performed significantly better in the water maze (*, p < 0.05; n = 7).  
 
Exercise up-regulates DJ-1 levels in α-synuclein transgenic mice 
Our previous in vitro studies show that in the presence of oxidative stress, cells 
will up-regulate DJ-1 expression in order to reduce reactive oxidative species; my 
hypothesis was that DJ-1 would be up-regulated to reduce the oxidative stress 
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accumulated during aerobic exercise in vivo in Y39C transgenic mice.  Results show that 
in wild-type mice after only a week of running wheel exercise, DJ-1 levels in the muscle 
and the blood plasma were significantly increased and DJ-1 levels in the brain were 
increased as well, although brain levels had not yet reached significance after one week.  
Consequently, I examined the DJ-1 levels in muscle, plasma and brain of Y39C Exercise 
and Non-Exercise mice after a 12 week exercise intervention.  Samples of thigh skeletal 
muscle tissue were obtained from sacrificed mice and analyzed using Western blot to 
detect   
DJ-1.  
 A representative Western blot image in Figure 45 shows that Exercise mice had 
significantly increased DJ-1 levels in skeletal muscle compared to Non-Exercise mice.  
Additionally, I used ELISA to measure plasma DJ-1 protein concentration collected 
during sacrifice.  On average, the plasma DJ-1 levels were more than double in the 
exercise group compared to the non-exercise group; these findings confirm the results 
seen in WT mice after one week of exercise (Fig. 46).  
 
Figure 45: Exercise increases DJ-1 expression in muscle of Y39C transgenic mice 
After 12 weeks of voluntary running wheel exercise, skeletal muscle samples from the 
Exercise and Non-Exercise transgenic mice were analyzed for DJ-1 levels using Western 
blot analysis.  Quantitative DJ-1 levels are shown for each group after the samples were 
normalized to β-actin.  There were significant increases in muscle DJ-1 in Exercise 






Figure 46:  Exercise increases DJ-1 levels in plasma of Y39C transgenic mice 
After 12 weeks of exercise intervention, plasma samples from Exercise and Non-exercise 
mice were collected and analyzed for DJ-1 concentration using a DJ-1 ELISA.  Exercise 
mice had more than double the concentration of DJ-1 in the plasma than did the Non-
exercise group on average (**, p < 0.01; n = 7). 
  

















Exercise Increases Plasma DJ-1 
  
p < 0.01 
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Finally, whole brain samples were analyzed for DJ-1 using Western blot. Brain 
DJ-1 levels were significantly increased in the exercise group compared to the non-
exercise group as shown in a representative Western blot in Figure 47.  The data showed 
that the exercise group of Y39C transgenic mice had significantly higher DJ-1 levels in 
the muscle, plasma and brain compared to the non-exercise group.  These results confirm 
the previous data observed in the wild-type mice after one week of exercise intervention 
that exercise can increase DJ-1 levels in muscle and plasma and suggests that brain DJ-1 
levels are significantly increased with more than one week of exercise intervention. 
 
Figure 47:  Exercise increases DJ-1 levels in brains of Y39C transgenic mice 
After 12 weeks of voluntary running wheel exercise, brain tissues were processed for 
Western blot analysis using the DJ-1 antibody and the β-actin antibody as a loading 
control.  Quantitative protein levels are shown for DJ-1 levels after normalization to β-
actin.  There was a significant increase in brain DJ-1 levels in Exercise mice compared to 
the Non-Exercise group (*, p < 0.05; n = 7). 
 
Exercise reduces α-synuclein aggregation in brains and increases α-synuclein level 
in plasma of transgenic mice 
A key neuropathological feature of the Y39C α-synuclein transgenic mice is the 
gradual accumulation of insoluble α-synuclein.  Our previous data has shown that the 
treatment with the drug phenylbutyrate can reduce the accumulation of α-synuclein in the 
brains and induce clearance of brain α-synuclein monomers and oligomers to the plasma 




hypothesize that the up-regulation of brain DJ-1 that was observed from a 12 week 
exercise intervention is sufficient to reduce brain α-synuclein aggregation and increase 
clearance of α-synuclein from the brain to the plasma in Y39C transgenic mice.   
After 12 weeks of voluntary running wheel exercise, whole brain tissue 
homogenates from Exercise and Non-exercise mice were collected and analyzed for       
α-synuclein content using Western blot.  Two different antibodies for α-synuclein were 
probed: LB509 antibody—which is specific to human α-synuclein—and SYN-1 
antibody—which recognizes both human and mouse homologs of α-synuclein.  In the 
Western blot analysis with LB509 antibody, results indicate that the Exercise group had 
significantly reduced human α-synuclein oligomer aggregation compared to Non-
Exercise transgenic mice.  While α-synuclein monomer levels were not significantly 
different between Exercise and Non-Exercise groups, the total α-synuclein levels in brain 
were significantly lower in the Exercise group as a result of the reduced levels of 
aggregates (Fig. 48A).  Similar results were observed using the SYN-1 human and mouse 
specific antibody:  mice in the Exercise group had significantly lower α-synuclein 
aggregates and therefore reduced total α-synuclein in the brain compared to the Non-
Exercise group while the monomer levels remained unchanged (Fig. 48B).  These results 
indicate that exercise intervention can both significantly up-regulate brain DJ-1 levels 
and significantly reduce brain α-synuclein aggregates in Y39C transgenic mice. 
While it is known that α-synuclein is primarily expressed in brain neurons, we 
and others have reported finding that α-synuclein can be detected in the plasma.  We have 
reported that in Y39C transgenic mice, in which human α-synuclein transgene is 




Figure 48:  Exercise reduced α-synuclein oligomer formation in brains of Y39C 
transgenic mice 
After 12 weeks of voluntary running wheel exercise, Exercise and Non-Exercise mice 
were sacrificed and brain tissues were analyzed for α-synuclein aggregation using LB509 
(human-specific) and Syn-1 (mouse- and human-specific) antibodies.  A) A 
representative Western blot with LB509 antibody showed dramatically reduced human α-
synuclein oligomer formation in the brains of Exercise mice compared to the Non-
Exercise group; however, the human α-synuclein monomer levels were not changed.  B) 
A representative Western blot with Syn-1 antibody showed that exercise reduce both α-
synuclein oligomer and dimer fractions compared to Non-Exercise mice. Additionally, 
these Western blots show that the total α-synuclein content in the transgenic mice is 50% 
human α-synuclein and 50% mouse α-synuclein and that this ratio is unchanged with 
exercise intervention.  The quantitative levels of α-synuclein oligomers, monomer and 
total (oligomer + monomer) normalized to β-actin is shown for the LB509 analysis and 





the human form of α-synuclein is detectable in the plasma.  This result verifies that there 
is a mechanism of clearance of α-synuclein from the brain to the plasma and that 
phenylbutyrate treatment enhances this mechanism.  Therefore, it is possible that the 
reduction of total α-synuclein and α-synuclein aggregates we observed in the mouse 
brains as a result of the 12 week exercise intervention is because of an increased 
activation of the α-synuclein clearance mechanism from the brain to the plasma. 
Therefore, plasma samples were examined by Western blot from Exercise and Non-
Exercise groups using Western blot analysis with LB509 human-specific and SYN-1 
mouse- and human-specific α-synuclein antibodies.  Results show the Exercise group had 
significantly higher levels of brain-derived human α-synuclein than did the Non-Exercise 
group, in both the monomer and oligomer fractions (Fig. 49A).  Similarly, when probed 
with the SYN-1 antibody, the Exercise group showed significantly higher levels of both 
α-synuclein monomers and oligomers compared to the Non-Exercise group (Fig. 49B).  
Taken together, these data demonstrate that exercise is sufficient to up-regulate DJ-1, 
reduce neurotoxic α-synuclein aggregates in the brain and enhance the clearance 
mechanism of α-synuclein from the brain to the plasma of Y39C α-synuclein transgenic 
animals. 
Discussion 
The animal studies performed reveal the neuroprotective effects of aerobic 
exercise intervention in vivo. These results show for the first time that exercise can 
dramatically reduce brain α-synuclein oligomer formation and significantly improve 
motor and cognitive function in the Y39C α-synuclein transgenic mouse model of 
progressive diffuse Lewy body disease.  Additionally, the findings demonstrate that 
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exercise is sufficient to up-regulate DJ-1 expression in the mouse brain.  Increased 
expression of DJ-1 provides dopamine neurons with protection against oxidative stress 
and α-synuclein induced toxicity (Shendelman et al, 2004; Zhou et al, 2005).  We have 
previously shown that increasing DJ-1 protein levels in cell culture and in Y39C α-
synuclein transgenic mice can prevent toxic α-synuclein aggregation.  Additionally, 
studies have shown that exercise can increase neurogenesis in the hippocampus and 
improve memory function in various mouse models (Alvarez-Lopez et al, 2013; 
Intlekofer et al, 2013).   Using the Y39C α-synuclein transgenic mice described 
previously, I have discovered that exercise can increase DJ-1 expression and therefore 
increase the neuroprotective mechanisms of DJ-1 (Zhou et al, 2008).  Additionally, 
results show that DJ-1 knock-out mice perform drastically less voluntary running wheel 
exercise.  I speculate that this phenomenon occurs because without the neuroprotective 
mechanisms of DJ-1 the mice experience a buildup of exercise induced oxidative stress. 
It has been reported that changes in levels of intercellular reactive oxygen species results 
in a reduction of the ability of the cell to regulate intercellular pH (Milner et al, 2007).  
Additionally, it is thought that physical exercise may cause pain both as an immediate 
pain effect that may result from stimulation of free nerve endings by low pH, as well as 
delayed onset muscle soreness (Nosaka, 2008).  I hypothesize that without the DJ-1 
protein to reduce excess reactive oxygen species, the mice are unable to regulate 
intercellular pH and the low pH results in an immediate pain effect; therefore the mice 
cease physical exercise.  In addition, there were higher levels of α-synuclein dimers and 
monomers in the mouse plasma from exercising mice compared to sedentary controls.    
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Figure 49:  Exercise enhances clearance of α-synuclein from the brain to the plasma 
of Y39C transgenic mice 
After 12 weeks of exercise intervention, mouse blood plasma samples were collected and 
processed for Western blot analysis with LB509 (human-specific) and Syn-1 (mouse- and 
human-specific) α-synuclein antibodies.  A representative Western blot for LB509 (A) 
and Syn-1 (B) show that both monomer and oligomer human and mouse α-synuclein 
were found in mouse plasma and that Exercise mice had increased levels of both 
monomer and dimer α-synuclein.  Quantitative α-synuclein levels were shown for each 
group after normalized to mouse albumin (*, p < 0.05; n = 7).  
 
 
Since α-synuclein is expressed exclusively in brain neurons, the presence in the plasma 
indicates a mechanism of brain-to-blood clearance.  The findings suggest that exercise is 
sufficient to enhance the mobilization process of α-synuclein from the brain to the blood.   
The FDA-approved drug phenylbutyrate can increase DJ-1 levels, prevent α-
synuclein aggregation in the brain and rescue the age-related decline in motor and 
cognitive function of Y39C α-synuclein transgenic mice.  The results from these 
voluntary exercise experiments conclude that exercise alone could achieve similar 




molecular mechanism for the clinical observations that exercise can be neuroprotective.  
The findings show for the first time that exercise is sufficient to up-regulate DJ-1 levels 
in the muscle, blood and brains of mice performing voluntary running.  The elevated 
levels of DJ-1 resulted in a rescue of motor and cognitive decline in the transgenic mice 
and enhanced clearance of toxic α-synuclein from the brains to the plasma of the 
transgenic mice.  Additionally, for the first time, the results revealed that the DJ-1 genetic 
knock-out mice have a behavioral phenotype of performing dramatically less voluntary 
running wheel exercise compared to wild-type mice.  While these mice are otherwise 
phenotypically identical to their wild-type littermates, I hypothesize that because these 
mice lack the DJ-1 protein essential for the reduction of excess oxidative stress, they 
perform less voluntary running.  During prolonged exercise, these mice have no 
mechanism of reduction of oxidative stress and therefore, they run significantly less than 
wild type mice.  In summary, exercise is sufficient to up-regulate DJ-1 and prevent 
progression of motor and cognitive decline in an α-synuclein transgenic model of diffuse 
Lewy body disease revealing a molecular basis for using exercise as a therapy for 
preventing the progression of disease in patients with Parkinson’s disease and diffuse 





SUMMARY AND FUTURE DIRECTIONS 
The practical goal of my thesis research was to identify potential new methods of 
therapy aimed at preventing further neurodegeneration and stopping the relentless 
progression of Parkinson’s disease.  The current gold standard of care for Parkinson’s 
disease is treatment with dopamine precursors which only temporarily alleviate the motor 
symptoms, but do nothing to prevent further neuronal death.  My research approach is to 
target and up-regulate the neuroprotection gene DJ-1 and activate protection pathways in 
order to clear toxic cellular stresses from the remaining dopamine neurons in Parkinson’s 
patients and halt the progression of disease.  Studies done prior to my thesis research 
revealed that DJ-1 is able to activate oxidative stress response pathways when cells are 
exposed to reactive oxygen species.  Separately, DJ-1 is able to up-regulate chaperone 
proteins when cells are exposed to protein aggregate toxins.  Since DJ-1 has shown to be 
neuroprotective, any therapy that could up-regulate DJ-1 without being harmful to cells 
could activate neuroprotection pathways in dopamine neurons in Parkinson’s patients 
thereby preventing future neuronal death and stopping the progression of disease.   
To thoroughly evaluate this hypothesis, I separated my research into distinct 
objectives.  The first objective is described in Chapter II:  I screened a number of small 
molecule drugs in vitro to examine their effects on DJ-1 expression.  The HDAC 
inhibitor phenylbutyrate up-regulated DJ-1 levels by 300% in dopamine neurons and did 
not have toxic effects on cellular viability.  This promising finding led to in vivo 
experiments to determine whether treatment with phenylbutyrate could prevent age-
dependent progression of disease phenotype in our transgenic mouse model of diffuse 
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Lewy body disease.  Results showed that transgenic mice treated with phenylbutyrate for 
three months had significantly higher levels of the neuroprotective gene DJ-1 in their 
brains.  As a result, mice treated with phenylbutyrate had significantly reduced motor and 
cognitive decline as well as reduced toxic α-synuclein protein pathology in the brains 
compared with transgenic mice not treated with phenylbutyrate.  The exciting results 
from my first objective verified that phenylbutyrate treatment is safe in transgenic mice 
and effectively up-regulates DJ-1 and can protect the mice from progression of disease 
phenotype.   
The results from my first objective led me to my second objective described in 
Chapter III and Chapter IV: to elucidate detailed mechanisms of action by which DJ-1 
up-regulation works to protect dopamine neurons from cell death.  I first needed to better 
understand why the mice treated with phenylbutyrate had significantly less toxic             
α-synuclein oligomers develop in the brain. I tested the possibility that the human mutant 
version of α-synuclein that was expressed only in the brain of our transgenic mice was 
able to be mobilized from the brain neurons to the blood plasma.  In fact, by using 
Western blot analysis, I was able to detect human α-synuclein in circulating plasma 
samples of transgenic mice. And, importantly, treatment with phenylbutyrate was able to 
significantly increase the levels of brain-derived α-synuclein in the mouse plasma.  These 
novel findings reveal that there is some biological mechanism of clearance of α-synuclein 
from brain neurons to blood plasma and that phenylbutyrate can somehow enhance this 
clearance mechanism.  The enhanced mobilization of α-synuclein with phenylbutyrate 
treatment explains the reduced brain α-synuclein oligomers I observed in the transgenic 
mice for my first objective.  I verified that α-synuclein clearance is enhanced by 
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phenylbutyrate treatment in both human patients with Parkinson’s disease involved in a 
human Phase I clinical safety trial and in cultured dopamine neurons.  
In Chapter IV, I address the next question I needed to answer for my second 
objective: how does phenylbutyrate and DJ-1up-regulation protect dopamine neurons 
from toxin induced cell death.  What are the cellular mechanisms by which dopamine 
neurons eliminate toxic oxidative stress and does DJ-1 help activate these pathways?  
Additionally, what are the cellular mechanisms by which α-synuclein is cleared from 
neurons to circulating plasma and how does DJ-1 enhance this mechanism?  To uncover 
which specific pathways were activated by phenylbutyrate to protect against the toxins of 
oxidative stress and abnormal α-synuclein aggregation, I performed an extensive in vitro 
RT-qPCR gene expression screen.  I screened the differential expression patterns of 
genes essential to a number of cellular pathways when cells were exposed to 
phenylbutyrate in addition to cellular stresses.  Results from this differential expression 
screen reveal that treatment with phenylbutyrate increases DJ-1 gene expression and 
protein levels.  Up-regulation of DJ-1 will activate the specific oxidative stress protection 
pathways in order to protect cells from hydrogen peroxide toxicity.  Through separate 
mechanisms of action, DJ-1 will activate protein catabolism pathways in order to protect 
cells from abnormal α-synuclein aggregate toxins.  Importantly, these findings reveal that 
healthy neurons utilize the lysosome/exosome protein catabolism pathway in order to 
eliminate toxic α-synuclein oligomers from dopamine neurons.  Results suggest that the 
efficiency of lysosome/exosome elimination is reduced in Parkinson’s patients resulting 
in the build-up of α-synuclein aggregates as Lewy bodies in the cells.  Phenylbutyrate 
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treatment and up-regulation of DJ-1 may activate the α-synuclein oligomer elimination 
through exosomes and prevent formation of Lewy bodies.   
The third objective, described in Chapter V investigated a non-pharmacologic 
therapy for up-regulating neuroprotective DJ-1 in patients with Parkinson’s disease.  The 
pursuit of this objective was the result of an interesting and unexpected observation from 
the human Phase I clinical safety trial of phenylbutyrate in newly diagnosed Parkinson’s 
patients. In the results of the transgenic mouse studies performed for my first objective, I 
observed that mice treated with phenylbutyrate had significant higher levels of DJ-1 
when compared to untreated animals.  Therefore, I expected that I would observe a dose-
dependent increase in plasma DJ-1 in patients as they increased the amounts 
phenylbutyrate treatments.  However, what I observed was that the plasma levels of DJ-1 
did not correlate to phenylbutyrate dose.  In fact, I observed that plasma DJ-1 levels were 
highly variable from patient-to-patient and from week-to-week.  Intriguingly, the only 
significant peak in normalized average DJ-1 levels of all the trial participants occurred 
over the two weeks from the winter holidays to the New Year.  This unexpected finding 
caused me to investigate environmental factors that may change during the holiday 
season that could affect DJ-1 levels in human beings.   One of the many possibilities was 
that Parkinson’s patients may become more physically active during the busy holiday 
season.  This hypothesis led me to investigate the neuroprotective effects of physical 
activity and exercise.  I observed that increased physical activity in the form of voluntary 
running wheel exercise in WT mice was sufficient to increase DJ-1 levels in muscle, 
plasma and brain.  Additionally, I found that DJ-1 is likely to be essential in efficient 
physical activity; I observed that DJ-1 genetic knock-out mice performed drastically less 
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voluntary running wheel activity than WT litter mates.  Finally, I observed that the up-
regulation of DJ-1 levels as a result of increased physical activity was sufficient to 
prevent the progression of Parkinson’s disease; voluntary running wheel exercise in our 
transgenic mouse model of diffuse Lewy body disease was sufficient to prevent the 
progressive development of motor and cognitive decline and was sufficient to enhance 
clearance of α-synuclein from the brain to the plasma.   Through the studies I performed 
to address the three objectives of my thesis research, I was able to verify my hypothesis 
that therapies that can up-regulate DJ-1 levels have been shown to reduce progression of 
Parkinson’s disease.  Both treatment with phenylbutyrate and increased physical exercise 
are promising therapies to pursue to prevent neurodegeneration and prevent the 
progression of disease in Parkinson’s patients.   
There are a number of future experiments that would be beneficial for better 
understanding both the pathogenesis of genetic and sporadic forms of Parkinson’s disease 
and also the neuroprotective function of DJ-1 gene and protein.  First, additional human 
clinical trials need to be done with phenylbutyrate treatment.  The initial Phase I human 
clinical safety trial of phenylbutyrate conducted during my thesis research involved only 
12 Parkinson’s patients and involved no healthy controls.  Additionally, this clinical trial 
was conducted with the initial hypothesis that there would be a dose-dependent increase 
in plasma DJ-1 corresponding to the dose of phenylbutyrate.  On the other hand, DJ-1 
levels were not an appropriate biomarker to track drug efficiency.  Interestingly, I did 
observe that plasma DJ-1 levels in Parkinson’s patients were highly variable and that the 
normalized average DJ-1 levels peaked between mid-December and early-January 
dependent of drug dose.  This unexpected “holiday phenomenon” led to an expanded 
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perspective of possible environmental factors, including activity level, that may affect 
human plasma DJ-1 levels.  Although plasma DJ-1 levels were not an effective biomarker 
for phenylbutyrate efficiency as expected, I did observe that when patients were taking a 
dose of 16 grams of phenylbutyrate a day there was a significant increase in plasma       
α-synuclein levels.  In future human studies, α-synuclein levels rather than DJ-1 levels 
will be tracked to determine efficacy of phenylbutyrate treatment.   
Additionally, since phenylbutyrate treatment was sufficient to enhance α-
synuclein clearance from the brains to the plasma of transgenic mice and humans with 
Parkinson’s disease, I performed and in vitro RT-qPCR gene expression screen to 
elucidate cellular mechanisms involved.  Results from the gene expression screen and 
subsequent Western blot analysis showed that phenylbutyrate treatment enhances 
clearance by activating the lysosome/exosome protein elimination pathway.  Therefore, I 
hypothesize that the increased levels of whole plasma α-synuclein levels may actually be 
increased α-synuclein levels within exosomes circulating in whole plasma.  In future 
clinical trials, exosomes will be isolated from whole plasma samples immediately after 
blood draws and exosomal α-synuclein content will be analyzed.  In addition, healthy 
age- and sex-matched controls will also be involved in future human clinical trials to 
investigate whether phenylbutyrate treatment enhances α-synuclein clearance in healthy 
individuals.  Importantly, average normalized α-synuclein levels in patients compared to 
controls will be assessed to determine whether treatment with phenylbutyrate can 
enhance α-synuclein clearance of Parkinson’s patients to the average levels of healthy 
controls.   
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Also, future experiments to better understand the neuroprotective effects of 
exercise in Parkinson’s patients would be valuable.  Results from exercise intervention 
experiments in a transgenic mouse model of Parkinson’s disease indicate, similar to 
phenylbutyrate treatment, that exercise is sufficient to up-regulate brain DJ-1 levels, 
enhance α-synuclein clearance mechanisms and prevent motor and cognitive decline.  I 
also observed that DJ-1 genetic knock-out mice performed significantly less voluntary 
exercise than did wild-type littermates.  My hypothesis is that without DJ-1 to activate 
oxidative stress response pathways, the knock-out mice have a much more rapid build-up 
of painful exercise-induced cellular reactive oxygen species and stop voluntary exercise 
sooner.  To test this hypothesis, rescue experiments can be performed with recombinant 
DJ-1 placed in a slow-release pump and implanted into the DJ-1 knock-out mice.  If my 
hypothesis is correct and DJ-1 is necessary for reducing exercise-induced reactive oxygen 
species, a recombinant DJ-1 protein pump will rescue the motor phenotype of the knock-
out mice and the mice will increase their voluntary running amounts to match their wild-
type littermates.  This result would underscore the importance of functional DJ-1 to 
eliminate reactive oxygen species, whether they build up from physical activity in 
skeletal muscle cells or from natural mitochondrial metabolism in dopamine neurons.  
These results would further indicate that therapies aimed at up-regulating DJ-1 are 
beneficial in preventing excess oxidative stress in these cells and stopping the progression 
of Parkinson’s disease. 
Through my thesis research, I have shown that treatment with the drug 
phenylbutyrate is sufficient to activate essential neuroprotective pathways in a transgenic 
mouse model of diffuse Lewy body disease and can enhance clearance of toxic               
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α-synuclein in Parkinson’s patients.  Additionally, I have shown that exercise 
intervention can up-regulate DJ-1 and activate essential neuroprotective pathways in a 
transgenic mouse model of diffuse Lewy body disease and prevent the age-dependent 
progression of phenotype in these animals.  It appears that both phenylbutyrate treatment 
and exercise intervention are sufficient to up-regulate DJ-1 in the brains of the transgenic 
animals.  Up-regulation of DJ-1 activates a number of neuroprotection pathways 
including oxidative stress response pathways, chaperone protein mediated ubiquitin 
proteasome pathways and the lysosome/exosome protein clearance pathways.  Future 
experiments should be done in transgenic mice to investigate the effects of combination 
therapy with phenylbutyrate treatment in addition to exercise intervention.  My 
hypothesis is that if each of these therapies is sufficient to up-regulate DJ-1 and slow the 
progression of disease, than the therapies in combination will enhance DJ-1 up-regulation 
further and have an additive effect on aborting disease progression.  Experiments can be 
done using the Y39C transgenic mouse model of diffuse Lewy body disease.  The mice 
will be divided into four groups: one group given phenylbutyrate in the drinking water 
and functional running wheels, one group given phenylbutyrate and fixed running 
wheels, one group given vehicle in the drinking water and functional running wheels and 
the fourth control group given vehicle and fixed running wheels.  If my hypothesis is 
correct, we will observe, as we have in the past, that the phenylbutyrate alone group and 
the exercise alone group will have significantly less disease progression than the un-
treated mice.  Most importantly, we will observe that the mice treated with both 
phenylbutyrate and exercise will have significantly less disease progression than the 
groups treated with phenylbutyrate or exercise alone.  This finding would indicate an 
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additive effect of both therapies I have research through a mechanism of DJ-1 up-
regulation.   
The findings of my thesis research may prove to be critically important in the 
Parkinson’s therapy research.  My research is aimed at finding a safe and effective 
therapy option for the prevention of progression of Parkinson’s disease.  Currently, the 
best treatment options for Parkinson’s disease are drugs that temporarily alleviate 
symptoms of disease but do nothing to prevent the neurodegeneration that causes the 
symptoms and, therefore, do not prevent the relentless progression of Parkinson’s 
disease.  My thesis research was to find forms of therapy that up-regulate the natural 
neuroprotective gene DJ-1 and by doing so activating natural cellular protection 
pathways within dopamine neurons and prevent further neurodegeneration.  I found that 
the drug phenylbutyrate is a safe and effective therapy for up-regulation of DJ-1, 
prevention of disease progression in a transgenic model of difuse Lewy body disease and 
is efficient to significantly enhance clearance of toxic α-synuclein from the brain to the 
plasma in humans with Parkinson’s disease.  Phenylbutyrate is a promising drug 
treatment to further pursue in human clinical trials as a therapy that prevents relentless 
progression of Parkinson’s rather than temporarily elevating symptoms.  Additionally, 
during my thesis research I have investigated the molecular mechanism that cause the 
neuroprotective effects observed clinically from exercise intervention.   I have found that 
like phenylbutyrate treatment, exercise intervention is sufficient to up-regulate DJ-1 and 
prevent progression of disease phenotype in a transgenic mouse model of diffuse Lewy 
body disease.  The use of exercise intervention alone—or in combination with 
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phenylbutyrate treatment—is a promising therapy to further investigate in human patients 
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